



(51) International Patent Classification:

C12N 5/0783 (2010.01) A61K 35/17 (2015.01)
A01N 1/02 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CA2019/051866

(22) International Filing Date:

19 December 2019 (19.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/782,005 19 December 2018 (19.12.2018) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK** [CA/CA]; 190 Elizabeth Street, R. Fraser Elliott Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: **ZHANG, Li**; 3 Weatherell Street, Toronto, Ontario M6S 1S6 (CA). **LEE, Jong Bok**; 763 Bay Street, Suite 2308, Toronto, Ontario M5G 2R3 (CA). **KANG, Hyeon-jeong**; 1807-7 Lorraine Dr., North York, Ontario M2N 7H2 (CA).

(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.**; Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRODUCTION AND THERAPEUTIC USE OF OFF-THE-SHELF DOUBLE NEGATIVE T CELLS




FIG. 1

(57) Abstract: Described are methods for the production and use of cryopreservable double negative T cells (DNTs) for the treatment of cancer as an off-the-shelf cellular therapy. A sample population of DNTs is expanded using DNTs from one or more donors. The expanded population of DNTs from different donors does not exhibit alloreactivity against allogenic cells in the expanded population. The expanded populations of DNTs can be long-term stored as cryopreserved products.



Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

PRODUCTION AND THERAPEUTIC USE OF OFF-THE-SHELF DOUBLE NEGATIVE T CELLS

RELATED APPLICATIONS

5 [0001] The present application claims priority to US provisional patent application no. 62/782,005 filed December 19, 2018, the entire contents of which are hereby incorporated by reference.

FIELD OF THE INVENTION

10 [0002] The present invention relates to double negative T cells (DNTs) and more specifically to the preparation of cryopreservable DNTs and the use of DNTs as an off-the-shelf adoptive cellular therapy for the treatment of cancer.

BACKGROUND OF THE INVENTION

15 [0003] The effectiveness of adoptive cellular therapy (ACT) using T cells to treat different hematological and solid malignancies has been demonstrated in multiple clinical studies.^{1,2} Advances in technologies such as genetically modifying immune cells to express a chimeric antigen receptor (CAR) or a transgenic-T cell receptor and use of artificial antigen presenting cells have been implemented to improve the therapeutic potency of ACTs.^{3,4} Recently, CD19-CAR T cell therapy achieved effective clinical responses in patients with B cell malignancies¹ and has
20 been FDA approved for clinical use for these diseases⁵. However, with increasing numbers of patients needed to be treated with ACT, limitations of current forms of ACT have become apparent, including sophisticated expansion methods resulting in uncertainty of producing therapeutically relevant numbers of T cells, time required for cell expansions, requirement of clinically-approved facilities for cell expansion,
25 inconsistency of manufactured cellular products, and high production costs.⁶

[0004] Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standardized second line of treatment with a long-term curative potential for patients with hematopoietic malignancies of multiple types.⁷ Therapeutic benefit of allo-HSCT comes from donor-derived immune cell-mediated graft-versus-leukemia

(GvL) effect targeting leukemic blasts that are resistant to conventional induction chemotherapies.⁷ Improved survival in patients receiving allo-HSCT demonstrates the potency of immune cell mediated GvL effect, but the effect is incomplete. To boost the GvL effect, patients can be treated with donor lymphocyte infusion (DLI),
5 where mature lymphocytes from the periphery of the HSC donor is given to the transplant-recipient as a prophylactic or therapeutic regimen to prevent or to treat the disease relapse post-transplant.⁸ Yet, recurrent disease remains the leading cause of mortality and is seen in 30-40% of allo-HSCT patients.⁹

[0005] Further, allo-HSCT is associated with high treatment-associated
10 toxicities. Of those, graft-versus-host disease (GvHD) is the leading cause of non-relapse mortality (NRM) in patients receiving allo-HSCT.^{10,11} GvHD occurs through donor-derived immune cells recognizing the normal allogeneic tissues of the recipients as foreign and attacking them. Acute GVHD is seen in 30-50% of treated patients with 14% suffering from more severe grade III or grade IV and chronic
15 GvHD is manifested in 30-70% of allo-HSCT recipients.^{10,11} GvHD significantly compromises patients' quality of life and increase their morbidity and mortality. Unfortunately, currently available immunosuppressant targets donor-derived T cells without distinguishing those inducing GvL effects and GvHD. Therefore, the side-effects of current forms of immunosuppressants include increased risk of disease
20 relapse and infections. Therefore, treatments that can induce GvL without GvHD or control GvHD while maintaining GvL when used in adjuvant with allo-HSCT are the 'Holy-Grail' for allo-HSCT patients.

[0006] Off-the-shelf ACT focuses on generating large batches of cells from allogeneic donors and using them to treat a large array of patients.¹² As this
25 approach is not patient-specific, cellular products can be pre-manufactured to save time.^{6,12} Mass production also increases product consistency, availability, and reliability at a lower cost. However, an effective clinically-applicable off-the-shelf allogeneic T cell therapy should meet the following criteria: 1) expandable to a therapeutically relevant number under clinically-compliant condition; 2) do not
30 cause graft vs. host disease (GvHD); 3) are able to target an array of cancers in a

donor-unrestricted manner; 4) are not rejected by recipient's immune system to enable sufficient persistence; 5) can be stored under GMP conditions without hampering their function. To best of our knowledge, there has not been a report to show an adoptive cellular therapy that has capacity of long-term storage and can
5 avoid host-versus-graft (HvG) rejection while fulfilling other requirements of off-the-shelf therapy without any genetic modification.

[0007] Double negative T cells (DNT) are mature T cells that comprises 3~5% of peripheral T cells and is defined by expression of CD3 in the absence of CD4 and CD8.¹³⁻¹⁵ Recently, healthy donor (HD) derived-allogeneic DNTs were
10 demonstrated to target acute myeloid leukemia (AML) *in vitro* and in patient-derived xenograft models and to have synergistic anti-cancer activities with conventional chemotherapies.¹³⁻¹⁵

SUMMARY OF THE INVENTION

[0008] In one aspect, the inventors have developed methods to expand
15 DNTs to therapeutic levels under GMP conditions that can be cryopreserved for long-term storage and characterized their surface molecule expression pattern using flow cytometry-based high throughput screening. The off-the-shelf potential of clinical-grade DNTs was investigated by assessing cytotoxicity induced by DNTs of various donor origin against multiple cancer types and their off-tumor toxicity *in*
20 *vitro* and in xenograft models and determining the effect of cryopreservation under GMP conditions on cell viability and function. Further, the susceptibility of DNTs to conventional allogeneic T cells *in vitro* and *in vivo* was determined.

[0009] In one aspect, the inventors investigated the application of off-the-shelf DNTs as a monotherapy or as an adjuvant to allogeneic hematopoietic stem
25 cell transplant (allo-HSCT) to treat cancer. DNTs-infused with peripheral mononuclear cells (PBMC) showed superior anti-leukemic activity than DNT-monotherapy and showed reduced off-tumor toxicities than PBMC-monotherapy in xenograft models.

[0010] Remarkably, as shown in Example 1 clinical-grade DNTs expanded 1558±795.5 fold in 17 days with >90% purity. Expanded DNTs showed potent *in vitro* cytotoxic activity against various cancer types in a donor-unrestricted manner, where DNTs from a single donor targeted multiple leukemia targets and DNTs from various donors show similar degree of anti-leukemia activity against same targets. DNTs enhanced the survival of mice infused with a lethal dose of Epstein-Barr virus transformed lymphoblastoid cell line (EBV-LCL) and significantly reduced leukemia engraftment in human leukemia-xenograft models. The inventors established a protocol to expand clinical-grade cryopreserveable DNTs and a protocol to optimally cryopreserve them using GMP-compliant reagents that maintained viability and anti-cancer functions for at least 600 days. Importantly, live allogeneic DNTs did not induce cytotoxicity of allo-reactive CD8⁺ T cells *in vitro*, and co-infusion of live DNTs with PBMC from a different donor into mice resulted in co-engraftment of DNTs and PBMC-derived allogeneic conventional T cells in the absence of cytotoxicity towards DNTs, suggesting the lack of host-versus-graft reaction. The methods described herein are therefore useful for generating therapeutic numbers of cryopreservable clinical-grade DNTs that fulfill the requirements of an off-the-shelf adoptive cell therapy.

[0011] As shown in Example 2, clinical-grade DNTs can be expanded from multiple different (allogenic) donors in the same culture without developing alloreactivity to each other during expansion. Characterization of the DNTs expanded *ex vivo* from pooled donor samples showed that the expanded allogenic cells maintained cytotoxicity against cancer cells without inducing cytotoxicity against normal cells or causing graft versus host disease (GvHD). Accordingly, in one embodiment there is provided a method of expanding a population of double negative T cells (DNTs) *ex vivo*, the method comprising:

- a) providing a sample population of DNTs, wherein the sample population of DNTs comprises DNTs from one or more donors; and
- b) culturing the sample population of DNTs in a culture media to produce an expanded population of DNTs, optionally a clinical-grade population of DNTs.

[0012] In one embodiment, the sample population of DNTs comprises DNTs from two or more donors. In one embodiment, the sample population of DNTs comprises DNTs from peripheral blood, leukapheresis, Leukopak, bone marrow and/or cord blood samples

5 [0013] In one embodiment, the DNTs from different donors are not alloreactive against one another in the expanded population of DNTs. In one embodiment, DNTs from different donors in the sample population are not alloreactive against each other. In one embodiment, the culture media is animal serum-free media. In one embodiment, the culture media further comprises human
10 blood-derived components, optionally human plasma, serum, or HSA. The human-blood-derived components may be autologous to the sample population of DNTs or allogenic. Optionally, the human-blood-derived components comprise plasma from one or more donors. In one embodiment, the concentration of human-blood-derived components in the culture media is about 1-20%. In one embodiment, the
15 concentration of plasma in the culture media is 2-15%. In one embodiment, the sample population of DNTs comprises DNTs from peripheral blood. In one embodiment, the expanded population of DNTs yields at least 0.1, 0.2, 0.5, 0.8 or 1.0×10^8 DNTs per milliliter of peripheral blood.

[0014] In one embodiment, the expanded population of DNTs comprises or
20 consists of at least 50%, 60%, 70%, 80%, 85% or 90% DNTs. In one embodiment, the method comprises splitting the cells to maintain a cell population above 0.1 million per ml of the culture media and below 4 million per ml of the culture media.

[0015] As shown Example 3, further investigations into the long-term cryopreservation of DNTs identified cryopreservation methods that preserved the
25 viability and cytotoxic activity of the cells for at least 600 days.

[0016] In one embodiment, there is provided a method of producing a population of double negative T cells (DNTs) for therapeutic applications. In one embodiment, the method comprises:

providing a sample population of DNTs, wherein the sample population of
30 DNTs comprises DNTs from one or more donors;

culturing the sample population of DNTs in a culture media to produce an expanded population of DNTs, optionally wherein the culture media is GMP-compliant;

re-suspending the expanded population of DNTs in a storage medium; and
5 optionally

adding DMSO to the storage medium to a final concentration of between about 3% and about 15% DMSO, optionally between about 5% and 10% DMSO.

[0017] In one embodiment, the method comprises adding DMSO to the storage medium to a final concentration of between about 3% and about 15%
10 DMSO, optionally between about 5% and 10% DMSO

[0018] Also provided is a method for cryopreserving DNTs. In one embodiment, the method comprises:

a) re-suspending a population of expanded DNTs in a storage medium;
b) adding DMSO to the storage medium to a final concentration of
15 between about 3% and about 15% DMSO; and

c) cryopreserving the population of DNTs in the storage medium at a temperature less than -70°C .

[0019] In one embodiment, the population of DNTs has been expanded *ex vivo*, optionally according to a method for expanding DNTs as described herein,
20 prior to re-suspending the population of DNTs in the storage medium.

[0020] In one embodiment, the final concentration of DMSO in the storage medium is from about 3% to about 15%, optionally from about 5% to 10%. In one embodiment, DMSO is added to the storage medium. In one embodiment, the DNTs are at a final concentration in the storage medium of between about 2.5×10^7 and
25 about 2.5×10^8 cells/ml, optionally between about 5 and 10×10^7 cells/ml.

[0021] Also provided is a population of DNTs produced, expanded and/or cryopreserved according to a method described herein. In one embodiment, the population is from a single expansion of DNTs from one or more donors and is for use or administration in one or more subjects for the treatment of cancer. In one

embodiment, the population of DNTs is from a single expansion of DNTs from one or more donors and is for use or administration in one or more treatments for one subject with cancer. In one embodiment, the population of DNTs comprises DNTs from two or more donors and is for use or administration for the treatment of cancer.

5 [0022] In one embodiment, the population of DNTs express CD3 and do not express CD4 or CD8 prior to expansion, and/or express CD3 and do not express CD4 or CD8 at least 5 days, 10 days, 14 days, 17 days, or 20 days post expansion.

[0023] In one embodiment, the population of DNTs are CD11a+, CD18+, CD10-, and/or TCR V α 24-J α 18-. In one embodiment, the population of DNTs are
10 DNTs are CD49d+, CD45+, CD58+ CD147+ CD98+ CD43+ CD66b- CD35- CD36- and/or CD103-.

[0024] In another aspect, there is provided a method of treating cancer in a subject in need thereof, the method comprises administering to the subject an effective amount of a population of DNTs as described herein, optionally in
15 combination with allo-HSCs and/or PBMCs. In one embodiment, the population of DNTs comprises allogenic DNTs from one or more donors, optionally two or more donors. Also provided is the use of a population of DNTs for treating cancer as a monotherapy or in combination with allo-HSCs and/or PBMCs, wherein the population of DNTs comprises allogenic DNTs from one or more donors, optionally
20 two or more donors. In one embodiment, the methods and uses described herein comprise the administration or use of DNTs as a monotherapy. In one embodiment, the methods and uses described herein comprise the administration or use of DNTs and allogenic HSCs and/or PBMCs at the same time. In another embodiment, the methods and uses described herein comprises the administration or use of DNTs
25 and allogenic HSCs and/or PBMCs at different times. Remarkably, as shown in Example 3 and Figure 18B, AML cells were not detectable in bone marrows of mice treated with PBMC followed by DNTs in an NSG xenograft mouse model of AML.

[0025] Also provided is a composition or kit comprising DNTs and HSCs. Also provided is a composition or kit comprising DNTs and PBMCs. In one

embodiment, the PBMCs are lymphocytes such as conventional CD4+ CD8+ T cells. In one embodiment, the DNTs described herein are for use in combination with donor lymphocyte infusion for the treatment of cancer in a subject in need thereof. In one embodiment, the kit comprises DNTs and HSCs and/or PBMCs in
5 in different containers.

[0026] In one embodiment, the DNTs have been expanded *ex vivo*, optionally wherein the allogenic DNTs have been expanded according to a method described herein.

[0027] In one embodiment, the DNTs from different donors are not
10 alloreactive against each other in the population of DNTs. In one embodiment, the population of DNTs is resistant to allogenic immune cell-mediated rejection in the subject *in vivo*. In one embodiment, the population of DNTs persists *in vivo* in the subject for at least 10 days, optionally for at least 2 weeks, at least 3 weeks, or at least 4 weeks.

15 [0028] Also provided are kits for expanding and/or cryopreserving a population of DNTs as described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Embodiments of the invention will now be described in relation to the drawings in which:

20 [0030] Figure 1. Clinical-grade DNTs expanded under GMP conditions. (A and B) Number of DNTs derived from each ml blood (A) and fold expansion (B) after 17 days culture are shown. Each symbol represents the result from one of 13 DNT cultures derived from 11 different donors C) DNTs expanded as described herein were stained with immune cell subset markers: CD3, CD4, and CD8 to check
25 the purity of cells. Result shown is a representative of DNTs expanded from 13 expansions. (D-I) Results of flow-cytometry based surface molecule high-throughput screening on expanded DNTs from three donors are shown. Histograms show representative results for T-cell associated markers, CD2, CD3, and CD5, and B cell associated markers, CD19 and CD20, to confirm the validity of the

screening method (D). Graphs show expression of T cell differentiation markers (E), chemokine receptors (F) cytotoxic (G), co-stimulatory (H), and co-inhibitory (I) molecules on expanded DNTs from three donors. Each symbol represents DNTs from one donor. Numbers shown are % of cells that expressed corresponding molecules on DNTs. Horizontal bars represent the mean \pm SEM. (J) Addition of TIM-3 antibody reduced the level of killing mediated by DNTs against AML3/OCI. (K) Addition of anti-CD3 antibody increased the killing mediated by DNTs against AML3/OCI.

[0031] Figure 2. DNTs induce cytotoxic activity against various cancer targets without off-tumor toxicity. A) Cytotoxicity of DNTs expanded from HDs against cell lines derived from various cancer types: myeloma (82), T cell leukemia (Jurkat), Burkitt's lymphoma (Daudi), AML (OCI/AML3), EBV-LCL, large cell lung cancer (H460), and adenocarcinoma (A549) using the *in vitro* flow cytometry-based killing assay as described herein. Experiments were done in triplicates and results shown are representative of more than 3 independent experiments for each target. B) *In vitro* killing assay performed using DNTs expanded from two HDs (HD1 and HD2) against two leukemia cell lines, OCI/AML3 and MV4-11, and a primary AML patient sample show that DNTs from a single donor kill multiple cancer targets. Experiments were done in triplicates. Result shown is representative of three separate experiments. C) *In vitro* killing assay were done using DNTs expanded from six HDs against the same cancer target, OCI/AML3, showing donor unrestricted activity of DNTs. Experiments were done in triplicates. The result shown is representative of three similar independent experiments. (D and E) NSG mice engrafted with EBV-LCL (D) or MV4-11 (E) were treated with three infusions of DNTs or PBS. D) Survival of EBV-LCL infused mice treated with DNT (n=6) or PBS (n=6) was monitored. Result shown is representative of three separate experiments done with DNTs from different donors. E) AML engraftment level in bone marrow was determined. Result shown is representative of four separate experiments. Each dot represents result from one mouse and horizontal bars represent the mean values \pm SEM of each group. F) *In vitro* killing assay conducted

against primary AML patient sample containing leukemic blasts and normal cells. Left flow panels show the gating strategy used to distinguish leukemic from normal cells. Histogram shows the absence of off-tumor toxicity mediated by DNTs while inducing potent cytotoxicity towards cancerous cells. Experiments were done in triplicates. Result shown is representative of four independent experiments done with different patient samples. (G and H) NSG mice inoculated with AML cell line MV4-11 were treated with PBS, human DNTs or PBMCs. 28 days post injection of AML, mice were euthanized and the liver and lung tissues were formalin fixed and stained with hematoxylin and eosin (H&E). G) Representative H&E stained slides of liver (400x magnification) and lung (200x magnification) from each group are shown. White arrows indicate bile ducts, grey arrows indicate bronchioles, and black arrows indicate the vessels. PV – portal vein; alv – alveoli. H) Tissue damage of H&E stained lung (left) and liver (right) slides were blindly scored by a pathologist. Each dot represent one mouse and horizontal bar represents the mean \pm SEM. Data shown are representative of four separate experiments. **, $p < 0.01$; ***, $p < 0.001$ ****, $p < 0.0001$, using unpaired, two-tailed Student's *t* test.

[0032] Figure 3. Allogeneic DNTs can be cryopreserved under clinically-compliant conditions while maintaining their function. (A and B) *Ex vivo* expanded DNTs were cryopreserved using an animal serum free reagent as described herein. The % viability (A) and *in vitro* cytotoxicity (B) of DNTs after freezing and thawing (FT) were compared to DNTs from the same expansion culture without FT C) Cryopreserved DNTs were used to treat NSG mice that were pre-infused with MV4-11 and the level of engraftment was determined in the bone marrow, as described in Figure 2E. D) Shelf-life of cryopreserved DNTs were determined by thawing DNTs frozen for different durations (617, 534, 276, 129, and 8 days) and checking their viability (left) and cytotoxicity (right) against a known DNT-susceptible cancer target (OCI/AML3). Data shown is representative of three similar experiments.

[0033] Figure 4. DNTs can persist *in vitro* and *in vivo* in the presence of allogeneic CD4⁺ and CD8⁺ T cells. (A-C) CFSE-labeled *ex vivo* expanded DNTs were intravenously injected into sublethally irradiated NSG mice (n=12). On days

indicated, cells from blood, spleen, bone marrow (BM), liver, and lung were stained with anti-human CD45 and CD3 antibodies, and DNTs were detected by flow cytometry (A, n=3 per day). CFSE median fluorescence intensity (MFI) of DNTs on days 0, 2, 7, 10, and 14 post injection was measured by flow cytometry. Histogram (B) and relative reduction of CFSE MFI with respect to day 0 CFSE MFI (C) are shown. The results shown the results obtained from 3 mice per time point and are representative of two separate experiments using DNTs from two different HDs. (D-G) Mixed lymphocyte reaction (MLR) was conducted using HD1 PBMC and HD2 expanded DNTs to determine the immunogenicity of expanded DNTs to allogeneic T cells. D) Schematic diagram shows the MLR conducted. E) CFSE-labeled or unlabeled HD1 PBMC were co-cultured with *live* or *irradiated* expanded HD1 or HD2 DNT for 4-6 days. At the end of the MLR, % increase in proliferating cells compared to the unstimulated control was determined as described herein. Left histogram shows the representative CFSE dilution, gated on CD8⁺ T cells. Experiments were done in triplicates, and the bar graph on the right shows the average of the triplicates. The results are representative of 2 separate experiments using different HDs for autologous and 5 separate experiments using 4 different HDs pairs for allogeneic DNTs. F) The level of cytotoxicity against DNTs by CD8⁺ T cells stimulated with live or irradiated autologous or allogeneic DNTs was determined. HD1 CD8⁺ T cells isolated post MLR were co-cultured with autologous (empty) or allogeneic (filled) DNTs at varying effector to target ratios. Results shown are representative of 5 independent experiments using 4 pairs of donors for allogeneic DNTs and 2 independent experiments with 2 pairs of donors for autologous DNTs. G) Sublethally irradiated mice were infused with HLA-A2⁺ PBMC and HLA-A2⁻ DNTs (n=5). 28 days post infusion, mice were sacrificed and cells from lungs were stained with human anti-CD45, anti-HLA-A2, anti-CD3, anti-CD4, and anti-CD8 antibodies and DAPI to determine the engraftment of human T cell subsets. Numbers represent the % of cells in the corresponding gates. Bar graphs show the frequency of HLA-A2⁺ CD4⁺/CD8⁺ T cells and HLA-A2⁻ DNTs in the lungs. Each dot represents a single mouse. Result shown is representative of two separate experiments.

[0034] Figure 5. Characterization of healthy donor (HD) DNT expansion using GMP-grade reagents. DNTs were expanded *ex vivo* with GMP-grade reagents including two types of animal-serum free media (AIM V and GT-T551). (A and B) Expansion profile (A) and purity (B) of DNTs from the same donor using two
5 different culture media. C) Cytotoxicity of DNTs expanded using two types of media against OCI/AML3 and MV4-11. The results are representative of 3 experiments using 3 HDs. *, $p < 0.01$.

[0035] Figure 6. Mixing of DNTs from two different donors retains anti-leukemic function without alloreactivity against each other. A) *In vitro* flow cytometry
10 based killing assay conducted against AML cell line using HLA-A2⁻ DNTs, HLA-A2⁺ DNTs, and the two donor DNTs mixed at 1:1 ratio. B) % dead DNTs from each donor with or without mixing was determined by flow cytometry after 2-hour co-incubation. The results are representative of two separate experiments using two different sets of HD DNTs.

15 [0036] Figure 7. Co-engrafted allogeneic CD8⁺ T cells are not cytotoxic against DNTs. Sublethally irradiated mice were infused with HLA-A2⁺ PBMC and HLA-A2⁻ DNTs. Four weeks post PBMC infusion, mice were sacrificed and cells from spleens were pooled and HLA-A2⁺ CD8⁺ T cells were isolated. Isolated CD8⁺ T cells were used as effector cells against the HLA-A2⁻ DNTs originally used for
20 xenograft experiment in an *in vitro* killing assay at 4:1 CD8:DNT for 14 hours. Flow plots show the viability of HLA-A2⁻ DNTs with or without coculture with HLA-A2⁺ CD8⁺ T cells. Result shown is representative of two separate experiments.

[0037] Figure 8. Off-the-shelf potential of allogeneic DNTs. A) DNTs expanded from different HDs show similar levels of cytotoxicity against the same
25 AML blasts. Killing assays were done by using DNTs expanded from 6 HDs as effectors against leukemia cells. B) Killing assay performed using DNTs expanded from 2 different HDs against primary and immortalized AML samples, demonstrating that DNTs from a single HD can target an array of AML samples.

[0038] Figure 9. Identifying optimal concentration of DMSO in cryopreservative reagent for freezing of *ex vivo* expanded DNTs. (A and B) Ex vivo
30

expanded DNTs from healthy donors using methods described herein were frozen in FBS containing 5%, 7.5%, or 10% DMSO. Viability of thawed DNT cells was determined by Annexin V staining on flow cytometry (A) and the cytotoxic function were determined by flow based killing assay against leukemia cell line (B).

5 Horizontal bars represent the mean and error bars represent \pm SEM. Unpaired, two-tailed Student's *t* test was used for statistical analysis.

[0039] Figure 10. Effect of animal serum in freezing media on the viability and anti-leukemic activity of cryopreserved expanded DNT cells. (A and B) *Ex vivo* expanded DNT cells from a same culture were frozen in freezing media containing
10 same concentration of DMSO with or without animal serum: FBS+7.5% DMSO and Cryostor+7.5% DMSO, respectively. Viability of thawed cells (A) and their anti-leukemic function (B) were determined as described in Figure 9. Horizontal bars represent the mean and error bars represent \pm SEM. Unpaired, two-tailed Student's *t* test was used for statistical analysis.

15 [0040] Figure 11. Validating the viability and the function of expanded cryopreserved DNTs. (A and B) *Ex vivo* expanded DNT cells from a same culture was either frozen or kept in culture. After thawing, viability of thawed cells (A) and their anti-leukemic function (B) were compared with DNTs that were kept in culture
20 without freezing as described in Figure 9. Horizontal bars represent the mean and error bars represent \pm SEM. Unpaired, two-tailed Student's *t* test was used for statistical analysis. (C) Immunodeficient NSG mice were engrafted with primary AML sample, and was treated with PBS or thawed DNTs. Harvested bone marrow cells were stained with anti-human CD45 and CD33 antibody and analyzed on flow
25 cytometry to determine the level of AML engraftment. Each dot represents a mouse, the bar represent the mean, and error bars represent \pm SEM. Unpaired, two-tailed Student's *t* test was used for statistical analysis: * $p < 0.05$.

[0041] Figure 12. Number of DNTs acquired at the end of 14-17 day *ex vivo* expansion using a previously established research-grade expansion method and the newly established GMP-grade expansion method described herein.

[0042] Figure 13. *Ex vivo* expansion of DNTs in the presence or absence of plasma (a) or HSA (b) using GMP-expansion method as described herein.

[0043] Figure 14. *Ex vivo* expansion of DNTs with addition of plasma obtained from autologous (empty symbol) and two allogeneic donors (filled symbols) using GMP-expansion method described herein. (b and c) Viability (b) and anti-cancer activity (c) of *ex vivo* expanded DNTs against an AML cell line, AML3/OCI using autologous and allogeneic plasma.

[0044] Figure 15. Expansion of pooled donor DNTs. a) Composition of HLA-A2⁻ (HD1) and HLA-A2⁺ (HD2) DNTs at the start (left) and at the end (right) of pooled donor DNT expansion culture determined by HLA-A2 expression pattern. b) Expansion profile of HD1 and HD2 DNTs, and DNTs mixed from HD1 and HD2 at 1:1 at the start of expansion. c) Viability of DNTs at the end of expansion gated on HLA-A2⁺ (left) and HLA-A2⁻ (right) DNTs. d) Purity of HD1, HD2, and HD1 and HD2 mixed DNT cultures at the end of expansion. Numbers represent the frequency of cells at each gate e) Cytotoxicity of HD1, HD2, and mixed DNTs against two AML cell lines, AML3/OCI (left) and MV4-11 (right) at varying effector: target ratio.

[0045] Figure 16. DNTs obtained from HLA-A2⁻ and HLA-A2⁺ donors were pooled and expanded for 20 days. HLA-A2⁻ and HLA-A2⁺ DNTs were isolated at the end of expansion of mixed DNTs and used as effector cells against autologous (filled) and allogeneic (empty) DNTs. HD1 conventional CD4⁺ and CD8⁺ T cells (T_{conv}) stimulated with HD2 DNTs was used as a positive control.

[0046] Figure 17. Efficacy and safety of DNT therapy in combination with PBMC. (A and B) Leukemia-bearing mice were treated with DNT, PBMC, or DNT+PBMC. A) Efficacy of each treatments was assessed by determining the level of leukemia engraftment in bone marrow. B) The level of tissue damage caused by each treatment were blindly assessed by a pathologist as described in Figure 2. C) Survival of naïve NSG mice treated with xenogeneic GvHD-inducing human PBMC with or without DNTs.

[0047] Figure 18. DNT therapy enhances the overall anti-leukemic activity without hampering graft vs. leukemia (GvL) activity mediated by T_{conv} cells. (A and B) Schematic diagram showing the experimental model used to determine the additive anti-leukemic activity of DNT cells when combined with PBMC (A). Flow cytometry plots are representative of bone marrow leukemia engraftment in mice treated with PBMC+PBS and PBMC+DNT. The dot graph shows the summary of leukemia engraftment levels in each treatment groups (B). (C) The effect of DNT infusion on anti-leukemic activity of CD8⁺ T cells determined by comparing *ex vivo* cytotoxicity of CD8⁺ T cells isolated from mice treated with PBMC+PBS and PBMC+DNT cells against the same leukemia target used for engraftment.

[0048] Figure 19. DNTs obtained from PBMCs instead of whole blood can be expanded with comparable expansion fold, purity, and anti-leukemic function. DNTs were isolated from PBMCs obtained from whole blood or leukapheresis samples. A) Purity of PBMC-derived DNTs expanded for 17 days. B) Comparison of expansion folds between DNTs isolated from PBMC and DNTs obtained from whole blood as previously described¹⁶. C) Comparison of *in vitro* cytotoxicity of DNT as isolated from PBMC with those obtained from whole blood against OCI-AML3 and MV4-11.

DETAILED DESCRIPTION OF THE INVENTION

[0049] One of major limitations of using allogeneic T cell therapy in the clinic is the risk of GvHD by infused donor cells. Conventional approach in developing allogeneic T cell therapy relies on knocking out/down the TCR α using gene editing or RNA interference technologies, or immunosuppression.^{17,18} However, we have demonstrated that allogeneic DNTs do not attack normal PBMCs without knocking out its TCR and provide a novel method to overcome the GvHD issue for developing allogeneic off-the-shelf T cell therapy without the need to remove TCR. There is a possibility though that when DNTs are activated against a leukemic target, they may induce cytotoxicity to nearby normal cells. To assess the potential alloreactivity of *ex vivo* expanded HD DNTs against normal cells during their cancer-targeting activity, *in vitro* killing assay was conducted using allogeneic DNTs against AML

patient PB derived leukemic samples, which contained a mixture of leukemic cells and normal cells defined by CD33, CD34, and CD45 expression pattern (Figure 2F). Notably, DNTs induced potent cytotoxicity against two leukemic blast population (P1 and P2), but no cytotoxicity was seen against normal cell population (P3; Figure 2F), demonstrating that even in a single culture, DNTs can selectively recognize and target leukemic blasts and spare normal cells from the same recipient. To further validate this, human AML-bearing mice were treated with PBS, PBMC or DNTs. Consistent with the *in vitro* finding, a significant anti-cancer activity of DNTs was observed in xenograft models, but DNT-treated mice did not exhibit signs of xenogeneic GvHD, unlike PBMC treated group (Figure 2G). Liver tissue from PBMC treated mice showed moderate portal lymphocytes infiltration and severe bile duct injury (white arrows). In contrast, DNT-treated mice showed mild portal lymphocyte infiltration but no bile duct injury. In lung, PBMC-treated mice show severe inflammation around vessels (black arrows) and bronchioles (grey arrows), and there are also endothelitis and septal inflammation around alveoli (alv). In contrast, DNT treated mice show no inflammation around vessels and bronchioles, and no endothelitis or septal inflammation around alveoli. Tissue damages seen in histology slides were blindly scored by a pathologist, and scored significantly lower tissue damage score in DNT-treated group than that of PBMC-treated (Figure 2H).

[0050] The persistence of infused immune cells has been shown to be correlated with treatment outcomes.¹⁹ Common limitation of allogeneic therapy is the quick rejection of infused cells by the host-immune system through a phenomenon called host-versus-graft (HvG) rejection.^{6,20} Conventional approaches to overcome the HvG issue for allogeneic T cell therapy attempt to disable the MHC-I by knocking out beta 2 microglobulin (beta-2M) chain through gene editing, or rely on immunosuppression.^{20,21} Here, it has surprisingly been determined that clinical-grade DNTs generated using the methods described herein do not induce alloreactivity, and can persist in the presence of allogeneic T cells without the need of gene editing to remove MHC-I, and provide a novel method to overcome the HvG

issue for developing allogeneic, off-the-shelf cell therapy without the need to remove MHC-I or MHC-II. Figure 4D shows the mixed-lymphocyte reaction (MLR) conducted to determine if allogeneic DNTs will induce alloreactivity of recipient's conventional T cells, where HD1 PBMC was cocultured with autologous DNT or
5 allogeneic DNTs from HD2. To determine if allogeneic DNTs carry allo-antigens that can activate conventional T cells, in another group, DNTs were irradiated prior to the MLR. As shown in Figure 4E, PBMC co-cultured with live or irradiated autologous DNTs and live allogeneic DNT showed no significant level of proliferation. In contrast, PBMC stimulated with irradiated allogeneic DNTs induced
10 a significant level of proliferation, suggesting that conventional alloreactive T cells are not activated by live DNTs, although DNTs do carry allo-antigens that can be recognized, as shown with irradiated allogeneic DNTs culture. Subsequently, CD8⁺ cytotoxic T cells were isolated from the MLR and used as effector cells against DNTs initially used for stimulation. While those stimulated with autologous DNT or
15 live allogeneic DNTs did not induce cytotoxicity, CD8⁺ T cells stimulated with irradiated allogeneic DNTs did, supporting the notion that live DNTs do not result in alloreactivity of conventional T cells (Figure 4F).

[0051] To validate this finding in vivo, NSG mice were infused with PBMC from HLA-A2⁺ donor and DNTs from HLA-A2⁻ donor (Figure 4G). Twenty-eight days
20 post infusion, cells from various tissues of the recipient mice were obtained and analyzed for the frequency of CD4⁺ and CD8⁺ T cells, DNTs and donor CD4⁺ and CD8⁺ T cells were identified by HLA-A2 expression. Persistence of HLA-A2⁺ CD4⁺ T cells, CD8⁺ T cells, and HLA-A2⁻ DNTs were detected in the same tissue, demonstrating that allogeneic DNTs can co-persist with conventional T cells. To
25 further investigate the allo-reactivity of engrafted CD8⁺ T cells, HLA-A2⁺ CD8⁺ T cells were subsequently isolated from DNT- and PBMC-treated mice and used as effectors against HLA-A2⁻ DNTs from the same donor origin as used for the xenograft experiment. No significant decrease in DNT cell viability was seen in the presence of isolated HLA-A2⁺ CD8⁺ T cells (Figure 7), demonstrating that allogeneic
30 CD8⁺ T cells did not develop alloreactivity against DNTs in a xenograft model.

Collectively, these data suggest that *ex vivo* expanded DNTs are resistant to allogeneic immune cell-mediated rejection and provide a foundation to further test the potential of allogeneic DNT as an off-the-shelf ACT that is resistant to HvG rejection in a clinical study.

5 [0052] As used herein, the term "cancer" refers to one of a group of diseases caused by the uncontrolled, abnormal growth of cells that can spread to adjoining tissues or other parts of the body. Cancer cells can form a solid tumor, in which the cancer cells are massed together, or exist as dispersed cells, as in a hematological cancer such as leukemia.

10 [0053] The term "cancer cell" refers a cell characterized by uncontrolled, abnormal growth and the ability to invade another tissue or a cell derived from such a cell. Cancer cells include, for example, a primary cancer cell obtained from a patient with cancer or cell line derived from such a cell. In one embodiment, the cancer cell is a hematological cancer cell such as a leukemic cell or a lymphoma
15 cell.

[0054] The term "subject" as used herein includes all members of the animal kingdom including mammals, and suitably refers to humans. Optionally, the term "subject" includes mammals that have been diagnosed with cancer or are in remission. In one embodiment, the term "subject" refers to a human having, or
20 suspected of having, cancer.

[0055] In one embodiment, the methods and uses described herein provide for the treatment of cancer. The term "treating" or "treatment" as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can
25 include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease (e.g. maintaining a patient in remission), preventing disease or preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and
30 remission (whether partial or total), whether detectable or undetectable. "Treating"

and "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. "Treating" and "treatment" as used herein also include prophylactic treatment. In one embodiment, treatment methods comprise administering to a subject a therapeutically effective amount of DNTs as described
5 herein and optionally consists of a single administration, or alternatively comprises a series of administrations.

[0056] In one embodiment, the methods and uses described herein involve the administration or use of an effective amount of DNTs. In one embodiment, the methods and uses described herein involve the administration or use of an effective
10 amount of DNTs in combination with allogenic hematopoietic stem cells (HSCs) and/or peripheral blood mononuclear cells (PBMCs). In one embodiment, the methods and uses described herein involve the administration or use of an effective amount of DNTs in combination with lymphocytes such as conventional T cells. In one embodiment, the PBMCs and/or lymphocytes are allogenic cells. As used
15 herein, the phrase "effective amount" or "therapeutically effective amount" means an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example in the context of treating cancer, an effective amount is an amount that for example induces remission, reduces tumor burden, and/or prevents tumor spread or growth of cancer cells compared to the response obtained
20 without administration of the compound. Effective amounts may vary according to factors such as the disease state, age, sex and weight of the animal. The amount of a given compound or population of cells that will correspond to such an amount will vary depending upon various factors, such as the given drug, compound or population of cells, the pharmaceutical formulation, the route of administration, the
25 type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art.

[0057] In one embodiment, the methods and compositions described herein involve the administration or use of DNTs. DNTs exhibit a number of characteristics that distinguish them from other kinds of T cells. In one embodiment, the DNTs do
30 not express CD4 or CD8. In one embodiment, the DNTs expanded for 10-20 days

express CD3-TCR complex and do not express CD4 and CD8. In one embodiment, expanded DNTs are also CD11a+, CD18+, CD10-, and/or TCR V α 24-J α 18-. In one embodiment, expanded DNTs are also CD49d+, CD45+, CD58+ CD147+ CD98+ CD43+ CD66b- CD35- CD36- and/or CD103-.

5 [0058] In one embodiment, the DNTs described herein express one or more surface markers, cytokines and/or chemokines. In one embodiment, the surface markers comprise one or more cytotoxic molecules such as perforin, granzymes TRAIL, NKG2D, DNAM-1, NKp30 and/or KIR2DS4, immune co-stimulatory molecules such as CD28, CD27, CD30, GITR, CD40L and/or HVEM, immune co-
10 inhibitory molecules such as TIM-3, LAIR1, NKG2A, CD94, LAG-3, CD160 and/or BTLA, adhesion molecules such as LFA-1, CD44, CD49d and/or CD62L, and/or chemokine receptors such as CXCR3, CCR3, CCR6 and/or CCR9, cytokine receptors such as CD122 and/or CD127.

[0059] In one embodiment, the DNT described herein have no or low
15 expression of immune co-inhibitory molecules PD-1, and/or CTLA-4, are resistant to PD-1 and/or CTLA-4 pathway mediated T cell suppression and exhaustion, and/or cancer immune suppression or escape mechanisms.

[0060] DNTs as described herein may be obtained using technologies known in the art such as, but not limited to, fluorescent activated cell sorting (FACS).

20 [0061] As used herein, the term "allogenic" refers to cells which are originally obtained from a subject who is a different individual than the intended recipient of said cells, but who is of the same species as the recipient. Optionally, allogenic cells may be cells from a cell culture. In a one embodiment, the DNTs are allogenic cells obtained from a healthy donor. As used herein the terms "healthy donor" ("HD")
25 refer to one or more subjects without cancer. In one embodiment, the healthy donor is a subject with no detectable cancer cells, such as a subject with no detectable leukemic cells.

[0062] In one embodiment, the DNTs and/or allogenic HSCs and/or PBMCs, optionally donor lymphocytes, may be formulated for use or prepared for

administration to a subject using pharmaceutically acceptable formulations known in the art. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. The term "pharmaceutically acceptable" means compatible with the treatment of animals, in particular, humans.

[0063] As used herein, "storage medium" refers to any cell culture medium understood by a person skilled in the art for used for the long-term preservation of mammalian cells (vs., for example, an expansion medium). Storage mediums include mediums optimized for the freezing/cryopreservation of cells (i.e. freezing medium or cryopreservation medium). Such mediums may contain animal serum (e.g. fetal bovine serum) or may be animal serum-free. Exemplary storage mediums include FBS with DMSO and Cryostor®.

[0064] As used herein, "cryopreservation" refers to the process by which cells, for example T-cells and preferably DNTs, are preserved by cooling to very low temperatures. Such low temperatures are -70°C to -90°C, preferably about -80°C using -80°C freezer, solid carbon dioxide or -196 °C using liquid nitrogen and are utilized to slow/stop any enzymatic or chemical activity which might cause damage to the cells. Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of intracellular ice crystals during freezing.

Methods for producing a population of DNTs, expanding cryopreservable off-the-shelf DNTs and/or cryopreserving expanded DNTs for clinical use

[0065] In one embodiment, there is provided a method of expanding a population of double negative T cells (DNTs) *ex vivo*. In one embodiment, the method is for expanding a population of cryopreservable off-the-shelf DNTs *ex vivo*. In one embodiment, the method comprises:

a) providing a sample population of DNTs, wherein the sample population of DNTs comprises DNTs from one or more donors; and

b) culturing the sample population of DNTs in a culture media to produce an expanded population of DNTs.

5 [0066] In one embodiment, the sample population of DNTs comprises DNTs from two or more donors. In one embodiment, culturing the sample population of DNTs in the culture media produces an expanded population of DNTs, optionally an expanded population of DNTs with more than 80% purity.

[0067] In one embodiment, the method comprises culturing the DNTs for at
10 least 5 days, 8 days or 10 days, optionally between 5 days and 20 days. In one embodiment, the DNTs are cultured for between about 8 days and 17 days. In one embodiment, the method comprises culturing the DNTs for at least 5 days, at least 8 days, at least 10 days, at least 12 days, at least 14 days, at least 17 days, at least 20 days, or at least 25 days, optionally between 10 days and 20 days.

15 [0068] As shown in the Examples, it has surprisingly been determined that DNTs from multiple donors do not exhibit alloreactivity against one another. Accordingly, in one embodiment the DNTs from different donors are not alloreactive against one other during expansion.

[0069] In one embodiment, allogenic DNTs from two or more donors are
20 combined prior to being expanded *ex vivo*. In one embodiment, allogenic DNTs from two or more donors are expanded *ex vivo* separately prior to being combined to form a population of DNTs.

[0070] In one embodiment, the culture media is animal serum-free media. In
25 one embodiment, the culture media comprises AIM-V, GT-T551, Stemline T cell Expansion Medium, Immunocult-XF T cell Expansion Medium, Human StemXVivo, Serum-Free Human T cell Base Media, CTS T-cell Expansion SFM, Prime-XV T cell expansion XSFM, or an equivalent animal-serum free human T-cell expansion media. In one embodiment, the culture media is GMP-compliant.

[0071] In one embodiment, the culture media further comprises human blood-derived components, plasma, serum, or HSA, optionally human plasma. In one embodiment, the human blood-derived components and DNTs may be from the same individual i.e. autologous to the sample population of DNTs. Remarkably, as shown in the Examples the DNTs may be expanded using human blood-derived components that is allogenic to the sample population of DNTs. For example, in one embodiment the plasma comprises pooled plasma from one or more donors, optionally two or more donors. In one embodiment, the concentration of human blood-derived components in the culture media is between 1-20%, optionally between about 2% and 15%.

[0072] In one embodiment, the culture media comprises soluble anti-CD3 antibody, IL-15, IL-7 and/or IL-2. In one embodiment, the culture media comprise recombinant or exogenous IL-2, IL-15, IL-7, IFN γ , an anti-4-1BB, anti-CD28, anti-OX40, anti-ICOS, anti-CD40, recombinant CD83, MIP-1a, IL-6, IL-8, IL-21, Jq1 inhibitor and/or anti-CD3. In one embodiment, the culture media does not comprise exogenous IL-4. For example, in one embodiment, the culture media comprises between about 50 and 500 or between about 50 and 800 IU/ml IL-2 and/or between about 0.05 and 1.0 μ g/ml anti-CD3. In one embodiment, the method comprises adding anti-CD3 antibody and/or IL-2 to the culture media.

[0073] As shown in Figure 12, the methods described herein are able to produce a significant expansion of DNTs from human samples. In one embodiment, the population of DNTs comprises DNTs from peripheral blood and the expanded population of DNTs yields at least 0.1, 0.2, 0.5, 0.8 or 1.0 $\times 10^8$ DNTs per milliliter of peripheral blood. The methods described herein also produce populations of DNTs with a relatively high level of purity. For example, in one embodiment, the expanded population of DNTs comprises or consists of at least 50%, 60%, 70%, 75%, or 80% DNTs, optionally at least 85% or 90% DNTs. In one embodiment, the expanded population of DNTs comprises at least 80% DNTs, optionally at least 85% or 90% DNTs.

[0074] In one embodiment, the method comprises splitting the cells in order to maintain a healthy and expanding cell population. In one embodiment, the method comprises splitting the cells to maintain a cell population above 0.1 million per ml of the culture media and below 4 million per ml of the culture media.

5 [0075] Various sources of a sample population of DNTs may be used to produce or expand a population of DNTs as described herein. For example, in one embodiment, wherein the sample population of DNTs comprises or consists of DNTs from peripheral blood, leukopheresis, Leukopak, bone marrow and/or cord blood samples.

10 [0076] In one embodiment, DNTs described herein are genetically modified. For example, in one embodiment, the DNTs are recombinant cells that have been modified to express one or more exogenous proteins. In one embodiment, the DNTs are genetically modified to enhance their anti-tumor activities and to reduce the risk to recipients.

15 [0077] In another embodiment, the DNTs are not genetically modified. In one embodiment, the DNTs are not genetically modified to reduce or prevent expression of TCR and/or MHC-I/II. In one embo

Methods for the Cryopreservation of DNTs

[0078] In one embodiment, there is provided a method for cryopreserving
20 double negative T cells (DNTs). In one embodiment the method comprises:

- a) re-suspending a population of DNTs in a storage medium;
- b) adding DMSO to the storage medium to a final concentration of between about 2.5% and about 15% DMSO; and
- c) cryopreserving the population of DNTs in the storage medium at a
25 temperature less than -70°C.

[0079] In one embodiment, the method comprises re-suspending a population of DNTs expanded using a method as described herein in the storage medium. In one embodiment, the method further comprises expanding a population

of DNTs using a method as described herein prior to re-suspending the population of DNTs in the storage medium.

[0080] In one embodiment, the method comprises cryopreserving the population of DNTs in the storage medium at a temperature between -70°C to -
5 90°C, preferably about -80°C.

[0081] In one embodiment, the population of DNTs has been expanded *ex vivo* prior to cryopreserving the cells. For example, the DNTs may be expanded *ex vivo* prior to cryopreserving the DNTs using a method for expanding a population of DNTs *ex vivo* as described herein.

10 [0082] In one embodiment, the cells are expanded *ex vivo* for between 5 and 25 days, optionally between about 8 and 14 days, or about 10 days prior to cryopreserving the cells. In one embodiment, the cells are expanded for between about 8 and 20 days prior to cryopreserving the cells.

[0083] In one embodiment, the method for cryopreserving the population of
15 DNTs described herein involves the addition of DMSO. In a preferred embodiment, DMSO is added dropwise to the storage medium. In one embodiment, the final concentration of DMSO is from about 3% to 15%, 4% to 10%, or from about 5% to about 8.5%. In one embodiment, the final concentration of DMSO is from about 7% to 8%, optionally about 7.5%.

20 [0084] In one embodiment, DMSO is added to the storage medium such that the rate of increase of the concentration of DMSO in the storage medium is controlled.

[0085] In one embodiment, wherein the DMSO prior to being added to the storage medium is at a concentration of about 10% to about 20%, optionally at a
25 concentration of about 10%, about 15% or about 20%.

[0086] In one embodiment, DNTs are at a final concentration in the storage medium of between about 2.5×10^7 and about 2.5×10^8 cells/ml optionally between about $5-10 \times 10^7$ cells/ml.

[0087] In one embodiment, the storage medium in contact with the DNTs is cooled. For example, in one embodiment, the population of DNTs is resuspended in storage medium cooled to less than 10°C but not frozen, optionally wherein the storage medium is cooled to about 8°C, 6°C, 4°C, or 2°C.

5 [0088] In one embodiment, the method further comprises after step b), but before step c), storing the population of DNTs at a temperature of about 1°C to about 7°C. In one embodiment, the method comprises storing the population of DNTs for between about 2 minutes and 20 minutes, optionally about 5 minutes, about 10 minutes or about 15 minutes.

10 [0089] As set out in the Examples, the choice of storage medium can impact the viability and/or activity of the DNTs. In one embodiment, the storage medium comprises animal serum, optionally fetal bovine serum. In one embodiment, the storage medium is animal serum free, preferably Cryostor™.

[0090] Optionally, cells cryopreserved according the method described
15 herein may then be stored at a temperature less than -130°C, optionally in liquid nitrogen. In one embodiment, the method comprises storing the population of DNTs at the temperature between -70°C to -90°C for at least 8 hours, at least 10 hours, at least 12 hours or at least 16 hours prior to storing the cryopreserved cells at the temperature less than -130°C.

20 *Pharmaceutical Compositions and Populations of Cells*

[0091] In one embodiment, there is provided a population of DNTs that has been expanded and/or cryopreserved according to a method as described herein. In one embodiment, the population of DNTs is for use in the treatment of cancer. Also provided is a population of DNTs that has been expanded, and/or
25 cryopreserved according to a method as described herein in combination with a population of hematopoietic stem cells (HSCs), wherein the DNTs and HSCs are from the same donor or different donors. In one embodiment, DNTs in combination with allogeneic HSCs showed enhanced anti-cancer activity while DNTs also reduces GvHD from allogeneic HSCs. Also provided is a population of DNTs that

has been expanded, and/or cryopreserved according to a method as described herein in combination with a population of PBMCs, optionally a population of lymphocytes such as conventional T cells, wherein the DNTs and PBMCs are from the same donor or different donors. In one embodiment, the use of DNTs in
5 combination with allogeneic PBMCs reduces GvHD from allogeneic PBMCs.

[0092] In one embodiment, the DNTs from a single expansion of DNTs from one or more donors and are for use or administration in one or more subjects for the treatment of cancer or for use or administration in one or more subjects for multiple treatments of cancer. In one embodiment, the DNTs are from a single
10 expansion of DNTs from two or more donors and are for use or administration in one or more subjects for the treatment of cancer or for use or administration in one or more subjects for multiple treatments of cancer. Also provided is a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a population of DNTs and optionally HSCs or PBMCs as
15 described herein. Also provided is the use of a population of DNTs and optionally HSCs or PBMCs as described herein for use in the preparation of a medicament, optionally a medicament for the treatment of cancer.

Methods and Uses of Allogenic DNTs for the Treatment of Cancer

[0093] As shown in the Examples, formulations comprising allogenic DNTs
20 from different donors have surprisingly been demonstrated to be useful for the treatment of cancer.

[0094] In one embodiment, there is provided a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a population of double negative T cells (DNTs), wherein the population
25 of DNTs comprises allogenic DNTs from one or more healthy donors (HDs). In one embodiment, the population of DNTs comprises allogenic DNTs from two or more HDs. Also provided is the use of an effective population of DNTs comprising allogenic DNTs from one or more donors or two or more donors for the treatment of cancer.

[0095] In one embodiment, the allogenic DNTs have been expanded *ex vivo*, optionally using a method as described herein. In one embodiment, allogenic DNTs from the two or more donors are combined prior to being expanded *ex vivo*. In another embodiment, allogenic DNTs from two or more donors are expanded *ex vivo* separately prior to being combined to form the population of DNTs. In one embodiment, the one or more donors are one or more subjects without cancer.

[0096] The populations of allogenic DNTs described herein exhibit a number of characteristics desirable for *in vivo* use for the treatment of cancer. In one embodiment, DNTs from different donors are not alloreactive against each other in a population of DNTs. In one embodiment, the population of DNTs is resistant to allogenic immune cell-mediated rejection in the subject *in vivo*.

[0097] In one embodiment, the DNTs persist *in vivo* in the subject for at least 10 days. In one embodiment, the population of DNTs persists in the subject for at least 2 weeks, at least 3 weeks, or at least 4 weeks. In one embodiment, the population of DNTs is not cytotoxic against normal cells *in vivo*.

[0098] In one embodiment, the population of DNTs has been cryopreserved prior to administering the population of DNTs to the subject, optionally by using a method for cryopreserving DNTs as described herein. In one embodiment, the population of DNTs has been cryopreserved without loss of viability and/or function. For example, in one embodiment, the population of DNTs can be cryopreserved for at least 10 days, 30 days, 60 days, 100 days, 300 days, 400 days or 600 days without loss of viability and /or function for the treatment of cancer.

[0099] In one embodiment, the population of DNTs is not genetically modified prior to their use or administration for the treatment of cancer. For example, in one embodiment the DNTs are not genetically modified to reduce or prevent expression of TCR and/or MHC-I/II. In one embodiment, the subject is not administered immunosuppression therapy prior to or during the administration of the population of DNTs for the treatment of cancer. In another embodiment, the subject is administered immunosuppression therapy prior to or during the administration of the population of DNTs for the treatment of cancer.

[00100] As shown in the Examples, DNTs described herein may be used in combination with allogenic hematopoietic stem cells (HSCs) and/or peripheral blood mononuclear cells (PBMCs) for the treatment of cancer. In one embodiment, the PBMCs are lymphocytes, optionally conventional T cells. Accordingly, in one
5 embodiment, the methods described herein include administering to a subject in need thereof DNTs and a population of cells comprising HSCs. In one embodiment, the methods described herein include administering to a subject in need thereof DNTs and population of cells comprising PBMCs. Also provided is the use of a population of DNTs as described herein in combination with a population
10 comprising allogenic HSCs for the treatment of cancer. Also provided is the use of a population of DNTs as described herein in combination with a population comprising allogenic PBMCs for the treatment of cancer.

[00101] In one embodiment, the DNTs are allogenic DNTs from a plurality of healthy donors, optionally wherein the DNTs are expanded according to a method
15 described herein.

[00102] In one embodiment, the subject is not administered immunosuppression therapy prior to or during the administration of the population of DNTs. In one embodiment, the DNTs described herein are for use or administration in a subject in the absence of immunosuppression therapy.

20 [00103] In one embodiment, the population of DNTs is from a single expansion of DNTs from one or more donors, optionally two or more donors, and for use or administration to a single cancer patient or to a plurality of cancer patients.

[00104] In one embodiment, the population of DNTs is from a single expansion of DNTs from one or more donors and is for use or administration to
25 multiple different subjects for the treatment of cancer.

[00105] In one embodiment, the DNTs are allogenic DNTs that have been expanded and/or cryopreserved *ex vivo*, optionally according to a method described herein.

- [00106] In one embodiment the DNTs are for use or administration to the subject at the same time as the HSCs and/or PBMCs or at different times. For example, in one embodiment the DNTs are for use or administration to the subject within 1 hours, 2 hours, 4 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 4 weeks, or more of the use or administration of the HSCs and/or PBMCs. In one embodiment, the combination of DNTs and HSCs and/or PBMCs is for the treatment of myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, or leukemias in the subject.
- 10 [00107] In one embodiment, the HSCs are from peripheral blood, leukapheresis, bone marrow or cord blood. In one embodiment, the allo-HSCs are mobilized using G-CSF. In one embodiment, the DNTs and HSCs are from the same donor. In one embodiment, the DNTs and HSCs are from different donor and optionally are allogenic DNTs and HSCs for use in the treatment of cancer.
- 15 [00108] In one embodiment, the PBMCs are lymphocytes, optionally conventional CD4+ CD8+ T cells. In one embodiment, the DNTs are for use or administration to the subject at the same time as the PBMCs or at different times.
- [00109] In one embodiment, the methods and uses described herein include inhibiting immune co-inhibitory molecules using anti-TIM3, anti-NKG2A, anti-LAIR1, anti-CD94, anti-LAG3, anti-CD160 and/or anti-BTLA antagonistic agents, and/or through enhancing immune co-stimulatory molecules using anti-CD28, anti-CD27, anti-GITR, anti-CD40L, anti-HVEM and/or anti-CD30 agonistic agents. In one embodiment, there is provided a method to enhance activity of DNTs, the method comprising inhibiting immune co-inhibitory molecules using anti-TIM3, anti-NKG2A, anti-LAIR1, anti-CD94, anti-LAG3, anti-CD160 and/or anti-BTLA antagonistic agents, and/or through enhancing immune co-stimulatory molecules using anti-CD28, anti-CD27, anti-GITR, anti-CD40L, anti-HVEM and/or anti-CD30 agonistic agents. In one embodiment, the method comprises the use or administration of anti-CD3 to enhance the anti-cancer activity of DNTs.
- 20
- 25

[00110] Accordingly, in one embodiment, the methods and uses described herein comprise the use or administration of anti-CD3 anti-TIM3, anti-NKG2A, anti-LAIR1, anti-CD94, anti-LAG3, anti-CD160 and/or anti-BTLA antagonistic agents, and/or anti-CD28, anti-CD27, anti-GITR, anti-CD40L, anti-HVEM and/or anti-CD30
5 agonistic agents. In one embodiment, the methods and uses described herein for the treatment of cancer further comprise the use or administration of an antibody to CD3. In one embodiment, the antibody to CD3 is for use or administration to the subject at the same time or at different times as the use or administration of the DNTs.

10 [00111] As shown in Figures 1J and 1K, the addition of TIM-3 or CD3 antibody modulated the level of killing mediated by DNTs against AML3/OCI. Combination therapy using DNTs and antibodies against molecules expressed on DNTs to improve their function is therefore expected to improve the therapeutic applications of DNTs for the treatment of cancer. In one embodiment, the antibodies are for use
15 or administration at the same time as the DNTs or at different times. For example, in one embodiment the DNTs are for use or administration to the subject within 1 hours, 2 hours, 4 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 4 weeks, or more of the use or administration of the antibodies.

20 [00112] Also provided is a method to modulate tissue trafficking and homing of DNTs. In one embodiment, the method comprises inducing or delivering adhesion ligands/receptors to CD44, CD49d and/or CD62L and/or chemokines to CXCR3, CCR3, CCR6 and/or CCR9 at desired target tissues and locations.

[00113] The following non-limiting examples are illustrative of the present
25 disclosure:

EXAMPLE 1: Allogeneic double negative T cells as an off-the-shelf adoptive cellular therapy for cancer

[00114] Adoptive T cell therapy is a practical treatment option for cancer
30 patients. However, with an increase in the clinical-use of adoptive cellular therapy

(ACT), its limitations, including high treatment costs and technical requirements, are becoming apparent and are restricting the wide clinical-use of ACT.²² Off-the-shelf allogeneic ACT has several advantages including lower treatment cost, reliable supply of cellular products and easy accessibility, but several requirements must
5 be met before its clinical applications.^{12,20} This example describes a straight-forward and easily applicable method to expand cryopreservable clinical-grade double negative T cells from healthy donors that fulfills the requirements of an off-the-shelf ACT: a therapy that targets various cancer types without apparent off-tumor toxicity; can overcome host-versus-graft reaction and achieve sufficient persistence; and is
10 storable. Remarkably, the use of DNTs as described herein represents a T cell therapy that can be used as an off-the-shelf therapy without any genetic modification.

Materials and Methods

Ex vivo expansion of DNTs under GMP conditions

15 [00115] DNT expansions were done as previously described²⁰ under GMP conditions with some modifications. Briefly, CD4⁺ and CD8⁺ cell-depleted PBMCs were cultured on anti-CD3 antibody-coated plates (GMP grade OKT3; Miltenyi) for 3 days in serum-free media (AIM-V (ThermoFisher) or GT-551 (Takara Bio)) with 250 IU/ml of IL-2 (Proleukin, Novartis Pharmaceuticals, Canada); soluble anti-CD3
20 antibody and IL-2 were added to the cultures. The purity of DNTs was assessed on days 0 and 10 of expansion as well as after harvesting before use for subsequent experiments. DNT purity was measured by staining cells with fluorochrome-conjugated anti-human CD3, -CD4, -CD8, and -CD56 antibodies and flow cytometry analysis. For validation runs, DNTs were expanded at the Philip S. Orsino Cell
25 Therapy Facility at Princess Margaret Cancer Centre or at Sunnybrook Research Institute GMP facility. To test for sterility, mycoplasma, and endotoxin, expanded DNT products were sent to Mount Sinai Hospital, WuXiApp Tech, and Princess Margaret Cancer Centre, respectively.

Flow cytometry-based in vitro killing assay

[00116] For non-adherent cancer cells, DNTs were co-cultured with target cells for 2-4 hours, cells were then stained with anti-human CD3 (HIT3a), CD33 (WM53), CD45 (HI30), and CD34(561) antibodies, Annexin V, and 7AAD (all from BioLegend), and analyzed using flow cytometry. Specific killing was calculated by

$$\frac{\% \text{ AnnexinV}^+_{\text{with DNT}} - \% \text{ AnnexinV}^+_{\text{without DNT}}}{100 - \% \text{ AnnexinV}^+_{\text{without DNT}}} \times 100.$$

5

[00117] For adherent cancer cells, cell lines were labelled with DiO (Invitrogen) and co-cultured with DNTs for 14 hr. All cells were collected after incubation in 0.25% trypsin-EDTA solution and stained with TO-PRO-3 (Life Technologies). Cell suspensions were analyzed by flow cytometry to determine specific lysis of labelled target cells. Specific killing was calculated by:

10

$$\frac{\% \text{ DiO}^+ \text{ TO PRO-3}^+_{\text{with DNT}} - \% \text{ DiO}^+ \text{ TO PRO-3}^+_{\text{without DNT}}}{100 - \% \text{ DiO}^+ \text{ TO PRO-3}^+_{\text{without DNT}}} \times 100.$$

Antibodies and flow cytometry

[00118] The following anti-human antibodies were used for cell staining: CD3-FITC or -PECy7, CD4-FITC or -PE, CD8-FITC or -PE, CD33-APC or -PECy5, CD56-PE, iNKT TCR (V α 24-J α 18 TCR)-APC, and Annexin V -FITC or -Pacific Blue and were purchased from BioLegend. Data acquisition was performed using either a BD Accuri C6 Flow cytometer (BD Bioscience) or an Attune NXT cytometer (ThermoFisher). Flow cytometry data were analyzed using FlowJo software (Tree Star, Inc.).

20 *High-throughput flow cytometry screening*

[00119] *Ex vivo* expanded DNTs were prepared for flow-cytometry based high-throughput screening as described previously.²³ Briefly, expanded DNTs were spun down and treated with FcX TrueStain (Biolegend) in PBS containing 0.5% BSA for 10 mins followed by staining with anti-CD3 PE-Cy7 antibody. Subsequently, cells were sent to Princess Margaret Genomics Centre, where cells

25

were stained with antibodies against 385 different cell surface molecules followed by staining with a viability dye, DAPI, prior to being analyzed by flow cytometry. Intracellular staining of CTLA-4 was performed using the protocol described herein. Data were analyzed using FlowJo software (Tree Star, Inc.).

5 *Cryopreservation of DNTs*

[00120] Day 7-20 *ex vivo* expanded DNTs were re-suspended in 4°C CryoStor2 (StemCell Tech.) containing 2% clinical-grade DMSO (StemCell Tech.), followed by adding an appropriate volume of CryoStor10 (StemCell Tech.) containing 10% DMSO to make the final concentration of DMSO at 7.5% and cell
 10 concentration at 5-10x10⁷ cells/ml. Cells were transferred to -80°C freezer in CoolCell™ (Fisher Scientific) to allow slow temperature decrease. Frozen cells were transferred to liquid nitrogen the next day for longer storage.

[00121] To thaw DNTs, cells taken from liquid nitrogen were thawed in a 37°C water- or bead-bath and serum was added at 20x the volume of cells. Cells were
 15 centrifuged at 300xg for 10 min. Pellets were resuspended at 10⁶ cells/ml with IL-2 and anti-CD3 (OKT3) antibody containing serum free culture media for further use.

Mixed lymphocyte reaction

[00122] CFSE-labeled or unlabeled PBMC obtained from healthy donors were co-cultured with live or irradiated expanded DNTs from autologous or allogeneic
 20 donor at 2:1 PBMC to DNT ratio for 4-6 days. Percent proliferating cells based on CFSE dilution was determined by flow cytometry. Percent increase in proliferation was calculated by:

$$\frac{\%Proliferated\ with\ DNT - \%Proliferated\ without\ DNT}{100 - \%Proliferated\ without\ DNT} \times 100.$$

[00123] To determine allo-reactivity, CD8⁺ T cells were isolated using a CD8-
 25 positive selection kit (StemCell Tech.) and isolated CD8⁺ T cells were co-cultured with DNTs at 4:1 CD8:DNT ratio for 4 to 14 hours. The cells were then stained with Annexin V and anti-CD8 antibody and analyzed by flow cytometry.

Xenograft models

[00124] For all xenograft experiments, NOD.Cg-*Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ* (NSG) mice (Jackson Laboratories, Bar Harbor, ME) maintained at the University Health Network (UHN) animal facility were used. To characterize persistence of DNTs, 8-
5 12 week old female mice were irradiated (250 cGy) 24 hours prior to a single injection of 5µM CFSE-labelled 2×10^7 DNTs. Cells from the bone marrow, spleen, liver, lungs, and peripheral blood were harvested on days 2, 7, 10, and 14, and the frequency of DNTs and CFSE dilution were determined by flow cytometry. To determine anti-cancer activity *in vivo*, irradiated NSG mice were infused with 1-
10 5×10^6 MV4-11 or EBV-LCL cells through tail vein injection. $1-3 \times 10^7$ DNTs were injected intravenously on days 3, 6, and 10 post-cancer cell injection. MV4-11 infused mice were sacrificed two weeks after the last DNT injection, and the engraftment of MV4-11 in the bone marrow was determined using flow cytometry as described previously²⁰. EBV-LCL infused mice were euthanized when their body
15 weight decreased by 20%. To assess the tissue damage, MV4-11 bearing mice were infused with DNTs, as described above, or PBMCs as a positive control. The liver and lung tissues were harvested and fixed in 10% formalin overnight and sent to Pathology Research Program Laboratory (Toronto General Hospital) for haematoxylin and eosin (H&E) staining. The H&E stained histology slides were
20 blindly scored by a pathologist for tissue damage following a previously described scoring method²⁴ with some modifications. The modified scoring method used is described herein. To determine the allo-reactivity of DNTs, mice were infused with $2-3 \times 10^6$ HLA-A2⁺ PBMC on day 0 and HLA-A2⁻ DNTs on day 0, 3, and 6. Four weeks post-infusion, cells from bone marrow, spleen, and lung were analyzed by
25 flow cytometry to monitor the engraftment level of human T cells. In all experiments, rIL-2 (Proleukin) was administered (10^4 IU/mouse) intraperitoneally at the time of DNT infusion and weekly after the last DNT injection until euthanization.

Statistical Analysis

[00125] All graphs and statistical analysis were generated using GraphPad
30 Prism 5. Student's *t*-test and linear regression test were used. * $p < 0.05$; ** $p < 0.01$;

p<0.001; *p<0.0001 indicate significance between experimental and control values. Error bars represent \pm SEM or SD as indicated.

Human samples and study approval

[00126] Human blood was collected from healthy adult donors after obtaining
5 written informed consent and used according to UHN Research Ethics Board (05-0221-T). Animal studies were approved by the Institutional Animal Care Committee of UHN (AUP: 741.22) and carried out in accordance with the Canadian Council on Animal Care Guidelines.

Antibodies, flow cytometry and ELISA

10 [00127] The following anti-human antibodies were used for cell staining: CD3-FITC or -PECy7, CD4-FITC or -PE, CD8-FITC or -PE, CD34-FITC or -PE, and CD33-APC or -PECy5 were purchased from BioLegend. Data acquisitions were performed using either BD Accuri C6 Flow cytometry (BD Bioscience) or LSRII (BD Biosciences) Flow cytometers and data were analyzed using FlowJo software (Tree
15 Star, Inc.).

Cell Lines

[00128] Cell lines, AML3/OCI, MV4-11, Jurkat, Daudi, H460, and A549 were obtained from ATCC KG1a, EBV-LCL was obtained from The Center for Applied Genomics at The Hospital for Sick Children. AML3/OCI were cultured in alpha-MEM
20 supplemented with 10% fetal bovine serum (FBS), EBV-LCL, Jurkat and Daudi were cultured in RPMI-1640 supplemented with 10% FBS, MV4-11 was cultured in IMDM supplemented with 10% FBS, H460 and A549 were maintained in DMEM/F12 supplemented with 10% FBS. All cell lines were incubated at 37°C in 5% CO₂.

25 *Intracellular staining of CTLA-4*

[00129] *Ex vivo* expanded DNTs surfaced stained with anti-human CD3, CD4, and CD8 antibodies, and fixed and permeabilized using intracellular fixation and permeabilization kit (eBioscience). Permeabilized cells were stained with anti-

CTLA-4 antibody (Clone L3D10) for 30 mins at 4°C. After washing, cells were analyzed by flow cytometry.

GvHD-model tissue damage scoring

[00130] Mice treated with PBS, DNT, or PBMC were sacrificed and liver and lung tissues harvested, fixed in 10% formalin, and H&E stained. Liver and lung histology slides were blindly scored by a pathologist following the scoring charts below:

Liver GVHD scoring

	0	1	2	3
Portal inflammation	Absent	Mild Present in fewer than 30% of portal tracts	Moderate Present in more 30%-50% of portal tracts	Severe Present in majority (more than 50%) of portal tracts
Lobular Inflammation	Absent	Mild With little hepatocytes necrosis or apoptosis	Moderate With focal necrosis causing confluence and/or several apoptosis	Severe With bridging/severe parenchymal necrosis
Bile duct injury	Absent	Mild Slight duct epithelium disorder with cytoplasmic eosinophilia	Moderate Duct epithelial disorganization with partial necrosis of affected ducts	Severe Extensive duct epithelial disorganization with complete necrosis of affected ducts
Bile duct loss	Absent	Mild Affecting 30% or less	Moderate Affecting 30-60%	Severe Affecting more than 60%
Cholestasis	Absent	Mild Visible only at 20X or higher magnification	Moderate Visible at 5-10x magnification but not easily	Severe Visible easily at 5x magnification
Total Score				

10 Lung GVHD Scoring

	0	1	2	3
inflammation	Absent	Mild Present around vessels without endotheliitis	Moderate Present with endotheliitis +/- septal expansion +/- mild alveolar extension	Severe Present with extensive septal expansion, heavy intra-alveolar inflammation +/-

Bronchial/bronchiolar Epithelial injury	Absent	Mild Subepithelial inflammation with no intra-epithelial inflammation	Moderate Subepithelial inflammation with intra-epithelial inflammation but no epithelial necrosis and/or apoptosis	Severe Subepithelial inflammation with intra-epithelial inflammation
Total Score (/6)				

Table 1: Scoring charts for GvHD-model tissue damage

Results

Ex vivo expansion and characterization of clinical-grade DNTs

[00131] Expansion of a cellular product under GMP conditions is required
 5 before its clinic application. Our previous studies were conducted with DNTs
 expanded using research grade reagents containing xenogeneic components.^{14,15}
 Use of animal-derived supplements restrict the use of final products for patient
 treatment due to risks associated with the xenogeneic additives.²⁴ To expand DNTs
 under GMP conditions, clinical-grade reagents were used and the yield, purity, and
 10 function of DNTs expanded using different types of animal-serum free media were
 compared (Figure 5). Subsequently, several parameters were investigated
 including cell concentration, IL-2 concentration, and the schedule of cell splitting.
 With an improved expansion method described herein, DNTs were expanded from
 11 donors in 13 cultures. By 17 days of expansion, $1.11 \pm 0.63 \times 10^8$ DNTs were
 15 generated from each milliliter of peripheral blood (PB; Figure 1A) with an average
 fold expansion of 1558 ± 795.5 (Figure 1B) and an average purity of $91.9\% \pm 4.29\%$
 (Figure 1C). To confirm our methods, three “validation-runs” were conducted in
 GMP-certified facilities. Similar yield, purity and cell stability in the infusion buffer
 were seen in all three runs, and all 3 batches of expanded DNTs passed tests for
 20 sterility, mycoplasma, and endotoxin.

[00132] To characterize the expanded DNTs, cell surface molecule
 expression profiling was performed on *ex vivo* expanded DNTs from three donors
 using the high-throughput flow cytometry screening method developed by Gedye
 C., *et al.*²³ DNTs stained with antibodies against 385 different surface molecules
 25 were analyzed by flow cytometry. The validity of the screening method was

confirmed by checking the expression of T cell associated markers, CD2, CD3, and CD5, and lack of expression for B cell markers, CD19 and CD20 (Figure 1D). Overall, *ex vivo* expanded DNTs display an effector memory T cell phenotype with expression of CD45RA, CD44, CD43, and CD49d and low or lack of CCR7, CD62L, BTLA, and CD127 expression (Figure 1E). *Ex vivo* expanded DNTs were positive for chemokine receptors, CXCR3 (38.0%), CCR3 (42.6%), CCR6 (20.1%), and CCR9 (17.6%) (Figure 1F), all of which are associated with recruitment of immune cells to inflammatory regions²⁵⁻²⁷, but were negative for other chemokine receptors.

[00133] To better understand immune responses mediated by DNTs, expression of cytotoxic molecules (Figure 1G), costimulatory molecules, (Figure 1H) and coinhibitory molecules (Figure 1I) were examined. Amongst the cytotoxic molecules, two previously identified molecules involved in DNT-mediated anti-leukemia activity, NKG2D and DNAM-1 were expressed at high levels (83.3% and 77.3%, respectively). Lower levels of other cytotoxic molecules, NKp30 (13.4%), KIR2DS4 (15.2%), and membrane-bound TRAIL (16.3%) were detected, but DNTs were negative for FasL, NKp44, NKp46, and KIR3DS1. DNTs expressed costimulatory molecules CD30 (49.5%), GITR (22.5%), CD27 (15.3%) and CD28 (25.2%), but expression of OX40, CD40, 4-1BB, and HVEM was very low or absent. Unlike most *ex vivo* expanded effector T cells, expanded DNTs were low for coinhibitory molecules, ICOS, CTLA-4 and PD-1, and PD-1 ligands, suggesting that DNTs may be resilient to T cell exhaustion or cancer immune escape mechanisms. However, high expression of TIM-3 (65.7%), LAIR1 (95%), and NKG2A/CD94 (58.9% and 42.6%) were also detected, suggesting a potential inhibitory activity of these molecules on DNT-mediated anti-cancer activity.

[00134] Combining the use of anti-TIM3, anti-NKG2A, and anti-CD94 antagonistic antibodies and anti-CD27, anti-CD28, anti-GITR, or anti-CD30 agonistic antibodies with DNT may promote the activities of DNTs. As migration of DNTs to target tissue is required for its activity, chemokine receptor expression pattern on DNTs may be used to promote migration of DNTs to desired tissues.

[00135] As shown in Figure 1J and 1K, addition of different antibodies can modulate the cytotoxicity of DNTs against AML. For example, addition of TIM-3 antibody reduced the level of killing mediated by DNTs against a relatively more resistant cell line, AML3/OCI, while cytotoxicity against highly susceptible leukemia line, MV4-11, remained comparable. In contrast, addition of anti-CD3 antibody increased the cytotoxicity of DNTs against AML3/OCI

Expanded DNTs target various types of cancers in vitro and in vivo in a non-donor restricted manner

[00136] For an off-the-shelf ACT, cells manufactured from a single donor should be able to target cancers from multiple patients in a donor-unrestricted manner. To determine the function of clinical-grade DNTs, the cytotoxicity of expanded cells towards various cancer cell lines derived from myeloma, T cell leukemia, Burkitt's lymphoma, AML, EBV-LCL, large cell lung cancer, and lung adenocarcinoma was examined *in vitro*. DNTs exhibited broad anti-cancer cytotoxicity toward all of the cancer targets tested (Figure 2A). Furthermore, clinical-grade DNTs from a single donor effectively targeted multiple cancer targets, OCI/AML3 and MV4-11 and a primary AML sample (Figure 2B) and similar levels of cytotoxicity were mediated by DNTs from six different donors against the same cancer target (Figure 2C). Further, mixing DNTs expanded from two different donors did not compromise the overall cytotoxicity compared to that induced by DNTs from either donor alone and donor DNTs showed no alloreactivity against each other when mixed *in vitro* (Figure 6). These results collectively demonstrate that DNTs induce a broad cancer-specific cytotoxicity in a donor-unrestricted fashion.

[00137] To determine the anti-tumor activity of DNTs *in vivo*, xenograft models were established with human EBV-LCL and AML in immunodeficient NOD.Cg-Prkdcscid Il2rg^{tm1Wjl}/SzJ (NSG) mice. In EBV-LCL xenograft model, mice inoculated with a lethal dose of EBV-LCL were treated with PBS or DNTs. All of the mice in the PBS-treated group died within 28 days (n=6), whereas four out of six DNT-treated mice survived through the length (85 days) of this study (Figure 2D).

Similarly, mice bearing human AML cells treated with DNTs showed 17.1-fold reduction in AML engraftment level in the bone marrow ($2.37 \pm 0.749\%$) compared to those treated with PBS ($40.5 \pm 4.56\%$) (Figure 2E). Interestingly, DNTs displayed a potent cytotoxic activity against primary AML patient cells expressing markers associated with leukemic blasts ($CD33^+ CD45^{low} CD34^+$ and $CD33^{high} CD34^+$) but not those with phenotype associated with normal cells ($CD33^- CD45^{high} CD34^-$) (Figure 2F) in the same killing assays, indicating that DNTs preferentially target leukemic cells but not normal cells. To further validate this result, the level of tissue damage caused by DNTs was assessed in an AML-xenograft model as described in 2E, and compared with those caused by PBMC. Consistent with the *in vitro* findings, a significant anti-cancer activity of DNTs was observed in xenograft models, but none of the cancer-bearing DNT-treated mice exhibited signs of xenogeneic GvHD (Figure 2G and 2H). Liver tissue from PBMC-treated mice showed moderate portal lymphocyte infiltration and severe bile duct injury, whereas DNT-treated mice showed mild portal lymphocyte infiltration without bile duct, vascular or other injuries (Figure 2G). In lungs, PBMC-treated mice showed severe inflammation around vessels and bronchioles, endotheliitis, and septal inflammation around alveoli. In contrast, DNT-treated mice showed no inflammation around vessels and bronchioles, and no endotheliitis or septal inflammation around alveoli were seen. The tissue damage in the livers and lungs was blindly scored by a pathologist and the DNT-treated group scored significantly lower than that from the PBMC-treated group (Figure 2H). Taken together, these data demonstrate that HD-derived DNTs expanded under GMP conditions are effective at targeting a broad range of cancer types *in vitro* and in xenograft models in a donor-unrestricted fashion without off-tumor toxicity, which are necessary features for a successful off-the-shelf allogeneic ACT.

Expanded DNTs can be cryopreserved under GMP conditions

[00138] Often the importance of cryopreserving expanded cells under a clinically compliant condition with negligible effect on cell viability and function is overlooked.²⁸ Effective cryopreservation methods allow for storage of manufactured

cells, increases the consistency of cell products, offers immediate availability of cell therapy for patient infusion, and provides a way to distribute cell therapy to areas that cannot manufacture cells, altogether increasing the flexibility and accessibility of ACT. To this end, multiple parameters were investigated to cryopreserve *ex vivo* expanded DNTs in a GMP-compliant animal serum-free media, including DMSO concentration, methods to add and remove DMSO, re-stimulation of thawed DNTs, and cell concentration for freezing. Optimally cryopreserved DNTs retained their viability (Figure 3A) and anti-leukemic activity *in vitro* (Figure 3B) and in a xenograft model (Figure 3C). To use cryopreserved DNTs as a ready-to-go product, their shelf-life as frozen cells is important. To investigate this, the viability and cytotoxicity of DNTs frozen for 617, 534, 276, 129, or 8 days were determined. All DNTs remained viable and retained their anti-leukemic function (Figure 3D). Collectively, DNTs expanded under clinically acceptable conditions can be cryopreserved in GMP-compliant media for at least 600 days without compromising their function, providing a way to use allogeneic DNTs as a “ready-to-go” treatment for cancer patients.

Live DNTs do not activate allogeneic immune response in vitro and can persist in vivo

[00139] The ability of adoptively transferred cells to persist in recipients affects the outcome of ACT²⁹, and its importance is more apparent in allogeneic settings as infused cells can be recognized and rejected by a patient’s immune system³⁰. Thus, the persistence, proliferative capacity, and migration patterns of DNTs *in vivo* were determined by systemically injecting CFSE-labeled *ex vivo* expanded human DNTs into naïve sublethally irradiated NSG mice. Cells from peripheral blood, spleen, bone marrow (BM), liver and lung were obtained on days 2, 7, 10 and 14 post-infusion. DNTs were detected in all tissues examined two days after infusion, and the frequency of DNTs decreased thereafter, but cells were still detectable 14 days after injection (Figure 4A). Compared to day 0, CFSE fluorescence intensity was diluted up to day 10 post-infusion but no further reduction from day 10 to day 14 (Figure 4B and 4C). These results demonstrate that DNTs migrate to different

tissues and undergo limited cell division *in vivo* and can be detected for at least two weeks after infusion into naive NSG mice.

[00140] The persistence of DNTs in naïve NSG mice, however, does not reflect their persistence in a clinical setting as immunodeficient mice are not able to reject the infused cells. To determine whether DNTs are prone to rejection by
5 allogeneic immune responses, we set up classical mixed-lymphocyte reaction (MLR) assays as shown schematically in Figure 4D. CFSE labeled PBMCs from one donor (HD1) were stimulated with *live* or *irradiated ex vivo* expanded DNTs from the same donor (HD1) or a different donor (HD2) to determine the
10 immunogenicity of allogeneic DNTs to conventional T cells. Stimulation with *irradiated allogeneic* DNTs increased proliferation of CD4⁺ and CD8⁺ T cells by 27.7% ± 0.12% and 37.7% ± 0.91%, respectively, which was significantly higher than that by *irradiated autologous* DNTs (13.7% ± 0.94% for CD4⁺ and 10.8% ± 0.12% for CD8⁺ T cells; Figure 4E). Interestingly, significantly lower degree of
15 proliferation of CD4⁺ (6.04% ± 0.69%) and CD8⁺ T cells (6.32% ± 0.55%) was induced by *live* allogeneic DNTs, which were comparable to the levels of proliferation induced by *live autologous* DNTs (6.61% ± 0.38% for CD4⁺ and 6.79% ± 0.21% for CD8⁺ T cells; Figure 4E). To further determine whether CD8⁺ T cells
20 co-cultured with autologous or allogeneic DNTs were able to target allogeneic DNTs, the CD8⁺ cells were isolated 4-6 days after coculture and used as effector cells against autologous or allogeneic DNTs as illustrated in Figure 4D. As expected, CD8⁺ T cells stimulated with *live* or *irradiated autologous* DNTs did not induce any cytotoxicity to allogeneic DNTs. Importantly, whereas CD8⁺ T cells stimulated by *irradiated* allogeneic DNTs elicited potent cytotoxicity against
25 allogeneic DNTs in a dose-dependent manner, no cytotoxicity of CD8⁺ T cells against allogeneic DNTs was detected when the CD8 cells were stimulated with *live* DNTs (Figure 4F). Collectively, these results demonstrate that while DNTs carry alloantigens, *live* allogeneic DNTs do not induce significant levels of alloreactivity of conventional T cells *in vitro*.

[00141] To further confirm that viable DNTs are resistant to allogeneic immune response *in vivo*, naïve NSG mice were infused with PBMC from an HLA-A2⁺ donor followed by 0 or 3 injections of HLA-A2⁻ DNTs from another donor. Four-weeks post-infusion, cells from the spleen, bone marrow, and lungs were isolated and engraftment of human T cells was determined. We found that in 4 out of 5 treated mice, a significant level of HLA-A2⁻ DNTs co-engrafted with HLA-A2⁺ CD4⁺ and CD8⁺ T cells in the same tissues (Figure 4G), indicating that DNTs persisted in the recipients for at least 4 weeks in the presence of allogeneic conventional T cells. To further investigate the allo-reactivity of engrafted CD8⁺ T cells, HLA-A2⁺ CD8⁺ T cells were subsequently isolated from DNT- and PBMC-treated mice and used as effectors against DNTs from the same donor origin as used for the xenograft experiment. No significant decrease in DNT cell viability was seen in the presence of isolated HLA-A2⁺ CD8⁺ T cells (Figure 7), further supporting that allogeneic CD8⁺ T cells did not cause elimination of DNTs in a xenograft model. Collectively, these data suggest that *ex vivo* expanded DNTs are resistant to allogeneic immune cell-mediated rejection and warrant further testing the potential of allogeneic DNTs as an off-the-shelf ACT that is resistant to HvG rejection in a clinical setting.

Discussion

[00142] While the efficacy and safety of a novel therapy are the priorities in the development of a new treatment, feasibility of translation into patient treatment should not be overlooked. Current forms of ACT take the “personalized” approach, generating cellular product for individual patients “on-demand” using a patients’ own immune cells and have achieved remarkable results in some patients but factors limiting their broad application have also become apparent from these studies.^{31,32} Therefore, off-the-shelf cell therapy that will allow more patient-accessibility is considered as the next generation of ACT.^{12,33}

[00143] An essential property of an off-the-shelf cellular product is its ability to target a broad range of cancers in a donor-independent manner. We have demonstrated that clinical-grade DNTs target an array of hematological and solid cancers *in vitro* (Figure 2A) and EBV-LCL and AML in xenograft models (Figure 2D

and 2E, respectively). In addition to cancer types presented in this study, we observed significantly inhibited non-small cell lung cancer progression after DNT treatment in xenograft models.³⁴ Notably, DNTs from a single donor could kill cancer cells of different origins (Figure 2B), and the level of cytotoxicity against the same cancer target was comparable between DNTs derived from different donors (Figure 2C) without observed off-tumor toxicity (Figure 2F and 2G). Further, cryopreservation of expanded DNTs under clinically compliant conditions did not compromise the function of DNTs (Figure 3). Collectively, these findings highlight the possibility of cryopreserving a large batch of expanded DNTs as a ready-to-go treatment for multiple patients.

[00144] One of the major concerns of using allogeneic T cells as a cellular therapy is the risk of GvHD.⁶ Jacoby *et al.* reported that infusion of allogeneic CD19-CAR T cells induced severe GvHD in the recipient mice due to the recognition of host allo-antigens by the endogenous TCR.³⁵ To address this issue, several groups knocked out the endogenous TCR from CD19-CAR T cells¹⁸ or transgenic TCR transduced T cells³⁶ and successfully prevented the onset of GvHD and maintained the anti-cancer activity. However, such approaches are limited to ACT against known tumor antigens as the use of exogenously transduced receptors against cancer-associated antigens is required to replace the lost anti-tumor specificity of the endogenous TCR, and impose another hurdle in cell production. We and others have previously shown that infusion of allogeneic mouse DNTs or xenogeneic human DNTs does not cause GvHD, unlike conventional CD4⁺ and CD8⁺ T cells.^{14,37} In line with previous findings, DNTs specifically targeted leukemic cells while sparing normal cells from the same patient sample in the same cytotoxicity assay (Figure 2F), and cancer-bearing mice treated with expanded human DNTs showed significant reduction in leukemia load without signs of toxicities on normal mouse tissues (Figure 2G). Taken together, these studies demonstrate that infusion of non-genetically modified allogeneic DNTs is unlikely to cause GvHD.

[00145] The persistence of infused immune cells has been shown to be correlated with treatment outcomes.¹⁹ Persistence of infused T cells are decided by

intrinsic and extrinsic factors. As a cell intrinsic factor, the activation status of infused cells can affect their persistence. We found that when DNTs were injected alone, they migrated and persisted in various tissues including the liver, lung, blood, bone marrow, and spleen of NSG mice up to 14 days (Figure 4A). Based on surface molecule profiling data, DNTs exhibited an effector memory phenotype (Figure 1E) that is associated with a more robust immune response and shorter persistence compared to central memory T cells.¹⁹ While the persistence of infused allogeneic DNTs in patients is currently under study in our phase I clinical trial, modifications to the cell expansion method may help to generate DNTs with a central memory phenotype if longer persistence is desired. Alternatively, such an issue can be overcome by using the off-the-shelf property of DNTs and re-infusing patients with cryopreserved DNTs as needed.

[00146] The major extrinsic factor affecting cell persistence is the rejection of infused cells by the host-immune system. Many studies on allogeneic ACT focuses on avoiding GvHD, but less so on HvG rejection. In one study conducted by Torakai *et al.*, HLA expression on allogeneic CAR-T cells was knocked out by genetic manipulation, which successfully evaded allogeneic CD8⁺ T cell-mediated cytotoxicity.²¹ However, the feasibility and safety of this approach in a clinical setting need to be validated. Interestingly, we found that stimulation of conventional T cells with live allogeneic DNTs does not elicit cytotoxic toward the allogeneic DNTs (Figure 4E). Further, co-infusion of allogeneic DNTs with PBMCs from a different donor resulted in their co-engraftment in NSG mice (Figure 4G) and co-engrafted allogeneic CD8⁺ T cells showed no allo-reactivity against DNTs (Figure 7). To our knowledge, this is the first form of allogeneic ACT that is resistant to HvG reaction without genetic modification or exogenous immunosuppressant. Nevertheless, given that irradiated allogeneic DNTs were potent stimulators of allo-reactive T cells, DNT viability for patient infusion needs to be carefully monitored to prevent the onset of HvG reaction.

[00147] The mechanisms by which live allogeneic DNTs evade rejection by conventional T cells are under study. We have shown previously that mouse DNTs

could kill allo-reactive CD8⁺ T cells that were activated by the same alloantigens that activated DNTs.³⁸ Furthermore, a higher DNTs versus CD8⁺ T cell ratio correlates with a less severe GvHD in allogeneic hematopoietic stem cell transplantation patients.³⁹ Collectively, these data support that, unlike conventional
5 T cells, infusion of viable allogeneic DNTs is less likely to result in rejection as the result of HvG reaction.

[00148] NK cells have potential to be used as an off-the-shelf therapy without genetic modification due to HLA-unrestricted anti-tumor function and limited GvHD causing activities.⁴⁰ NK-92, a cell line derived from a patient NK cell lymphoma, has
10 been shown to be safe and feasible as an off-the-shelf ACT in clinical studies.⁴⁰ However, only one study reported that out of 15 treated patients, two had mixed responses and one had stable disease. Limited anti-tumor activity may be due to short persistence as NK-92 were detectable only for ~48 hours after infusion⁴¹, possibly due to irradiation of the cells prior to patient infusion to avoid potential *in*
15 *vivo* tumorigenesis as they are immortalized cells. It is also possible that the infused NK92 were rejected due to HvG rejection⁴¹, which has not yet been studied. In a clinical study conducted by Romee *et al.*, infusion of cytokine-induced memory like allogeneic primary NK cells showed a more promising clinical response, where four out of nine AML patients achieved complete remission, in the absence of dose
20 limiting toxicity.⁴² However, donor-derived NK cells were not detectable by two to three weeks post infusion, suggesting that the host-immune system recovered and rejected donor-derived allogeneic NK cells or infused NK cells have a limited life expectancy. We found that significant numbers of DNTs were detected in mice 4 weeks after co-infusion with allogeneic PBMCs in the absence of lymphodepletion,
25 suggesting a better *in vivo* persistence of allogeneic DNTs than NK cells (Figure 4G).

[00149] In our previous study¹⁴, we have directly compared the cytotoxic activity of DNTs with NK-92 and expanded primary NK cells. We showed that while similar toxicity was seen against a known NK cell target, K562, superior killing was
30 mediated by DNTs against all seven AML targets tested, including four samples

resistant to NK-92 mediated cytotoxicity. Similarly, DNTs derived from healthy donors showed superior killing against AML cell lines than those of primary activated NK cells. This suggests that DNTs function through a different mechanism than that of NK cells, and DNTs may be able to target cancers resistant to NK-92.

5 Further, resistance of DNTs to HvG reaction may result in a longer persistence of DNTs in patients and therefore a more prolonged effect.

[00150] In summary, we have established a method to expand clinical-grade DNTs from healthy donors without genetic modification or extensive manipulations. To our knowledge, DNTs are the first T cell ACT that fulfills all the requirements of
10 an off-the-shelf allogeneic cell therapy without genetic alteration. The expanded DNTs can be cryopreserved, persist in an allogeneic environment in the absence of immunosuppression and are effective in targeting various cancers without off-tumor toxicity. These properties allow for the use of allogeneic DNTs as an off-the-shelf ACT for patients with different cancer types as a stand-alone therapy or in
15 combination with other conventional therapies. Further, DNTs can also be used in combination of antibodies that can modulate such as Tim-3, CD94/NKG2A, LAIR-1, CCR3, and CXCR3.

EXAMPLE 2: Cryopreservation and off-the-shelf potential of allogenic DNTs

[00151] It has been determined that allogeneic DNTs expanded from different
20 healthy donors showed similar level of cytotoxicity against a same AML target (Figure 8), and DNT cells from a single donor could target AML cells obtained from an array of AML patients (Figure 8), without any observed toxicity against normal cells. These findings suggest that the level of response by DNT therapy will be comparable regardless of the donor of which DNTs are derived from, and that DNTs
25 from a single donor can be used to treat multiple AML patients, supporting the potential for utilizing allogeneic DNT cells as an “off-the-shelf” therapeutic approach. However, lack of a storage method that can preserve the anti-leukemic function of *ex vivo* expanded DNTs impedes their use as “off-the-shelf” therapeutics.

30 *Functional analysis of expanded cryopreserved DNTs*

[00152] To determine the anti-leukemic function, cryopreserved DNTs were used as effector cells in *in vitro* cytotoxicity assay against cancer cell lines and none-frozen DNTs from the same donor or culture was used as a control. The anti-leukemic function of cryopreserved DNTs were further validated in an AML
5 xenograft model.

Cryopreservation of ex vivo expanded DNTs.

[00153] While the applicants have established a standard protocol to cryopreserve non-expanded DNT cells¹⁵, the same protocol could not preserve the function and viability of *ex vivo* expanded DNTs. Several parameters were modified
10 to develop an optimal freezing method for *ex-vivo* DNTs. First, the optimal concentration of DMSO in freezing media and method of adding DMSO was determined by comparing the viability and cytotoxic function of DNTs frozen in FBS + 5% DMSO, FBS + 7.5% DMSO, and FBS + 10% DMSO, It was found that DNTs frozen in FBS+7.5% had higher viability and cytotoxic function than those cells
15 frozen in FBS + 5% DMSO or 10% DMSO (Figure 9)

[00154] To test whether the use of animal serum can be avoided in the freezing process to ease the transition of the technology into clinic, the viability and cytotoxic function of DNTs frozen in FBS+7.5% DMSO and Cryostor+7.5% DMSO were compared, and showed that the viability (Figure 10) and cytotoxic function
20 (Figure 10) of cells from both freezing reagent were comparable.

Validating the function of ex vivo expanded DNTs post-cryopreservation.

[00155] While above studies showed the optimal method to cryopreserve expanded DNTs, we wanted to ensure that cryopreserved DNTs do not have compromised function compared to non-frozen DNTs. To this end, the *in vitro* anti-leukemic function expanded cryopreserved DNTs using the optimized protocols
25 described herein was compared to non-frozen DNTs expanded from the same donor or the same expansion culture. As showed in Figure 11 that both the viability and the cytotoxic function of DNTs were comparable. To further confirm that *in vivo* function of frozen cells is preserved, immunodeficient NSG mice were engrafted

with primary AML blasts were treated with thawed DNTs. Similar to none-frozen DNTs, cryopreserved DNTs significantly reduce the level of AML engraftment in a xenograft model (Figure 11).

[00156] Taken together, we have developed a method for cryopreservation of
5 ex vivo expanded DNTs by optimizing each step of cryopreservation methods. Using this method, we demonstrate that ex vivo expanded DNTs can be cryopreserved and maintain their anti-tumor function both in vitro and in vivo. This method allows DNTs to be stored as an “off-the-shelf” living drug to treat patients in need. It may also be applied to cryopreserving other expanded anti-tumor T cells,
10 NKT cells and NK cells for their research and clinical use.

EXAMPLE 3: Expansion of clinical grade DNTs for off-the-shelf allogenic cell therapy

[00157] Patent application no. PCT/CA2006/001870 describes a method for
15 ex vivo expansion of double negative T (DNT) cells. Using that method it is possible to generate 2.5×10^6 DNT cells from one milliliter of blood using expansion methods and reagents involving xenogeneic-additives. However, to produce DNTs for use in an off-the-shelf therapy, where DNTs obtained from a single expansion can be used for multiple treatments and/or patients, a higher DNT-yield is needed. Further DNTs generated using the previous method were research-grade. To allow translation of
20 DNT therapy to clinic, establishing methods to 1) improve the final cell yield 2) using clinically-compliant expansion methods and reagents were needed. Here, a new ex vivo DNT cell expansion protocol is described that results in clinical-grade DNTs with significantly improved the yield at the end of expansion.

[00158] Various parameters, such as cell concentration during expansion,
25 days of cell splitting, type and concentration of additives given during expansion, and different types of clinical-grade culture medium, were investigated. DNTs from healthy donors (HDs) expanded using newly established GMP-grade expansion method result in significantly higher number of DNTs at the end of expansion compared to those expanded using previously defined research-grade expansion
30 method (Figure 12).

[00159] As shown in Example 1 and Figure 5, DNTs expanded using two different clinically compliant culture media (AIM V and GT-T551) resulted in a significant difference in expansion. AIM V produced a higher number of cells and was used for subsequent DNT expansions.

5 [00160] The addition of plasma (Figure 13A), but not human serum albumin (HSA; Figure 13B), also significantly improves the expansion of HD-DNTs *ex vivo*.

[00161] Surprisingly, DNTs can be expanded using plasma from allogeneic sources which give comparable expansion profile (Figure 14A), viability (Figure 14B), and cytotoxicity against cancer cells (Figure 14C) as using autologous
10 plasma.

[00162] Surprisingly, DNTs derived from different donors can be mixed and expanded in the same culture (Figure 15A) without hampering their expansion profile (Figure 15B), viability (Figure 15C), purity (Figure 15D) or anti-cancer activity (Figure 15E).

15 [00163] To determine if DNTs expanded from pooled donor develop alloreactivity to each other during expansion, different donor derived DNTs were isolated using differentially expressed HLA subtypes and their cytotoxicity tested against each other. As shown in Figure 16, while conventional T cells derived from the same donors develop potent allo-reactivity, DNTs cocultured for 17 days do not
20 development of allo-reactivity against each other.

[00164] Despite allo-HSCT being the only consolidation therapy for many of hematological malignancies with long-term curative potential, its efficacy and safety need to be improved. To determine if DNTs can be used as an adjuvant to improve the efficacy and safety of allo-HSCT, cancer-bearing mice were infused with PBMC
25 with or without DNTs. Notably, co-infusion of DNTs with PBMC showed superior anti-leukemic activity than that of DNTs alone, and completely eradicated the cancer in all five treated mice, as oppose to 1 out of five treated mice with detectable level of cancer in PBMC-alone group (Figure 17A). Importantly, DNT co-infusion reduced the degree of GVHD induced by PBMC-derived T cells (Figure 17B). This

was further validated in a GvHD-xenograft model, where DNT-infusion significantly prolonged survival of mice treated with PBMC (Figure 17C).

[00165] Next, to determine if DNTs can enhance the overall anti-leukemia effect in leukemia-bearing host treated with PBMCs, NSG mice engrafted with an aggressive human AML cell line MV411 were treated with PBS, human PBMCs, ex vivo expanded DNTs or human PBMC followed by DNTs, and the leukemia engraftment level in the bone marrow was assessed (Figure 18A). As previously reported¹⁶, treatment with DNTs resulted in 50% reduction (from 20.6% ± 7.8% to 10.5% ± 3.7%) in leukemia burden compared to PBS control group, but the effect was incomplete (Figure 18B). PBMC-derived T_{conv} cells mediated a strong anti-leukemia response, reducing the AML level to 0.68% ± 0.27%, yet there were detectable residual leukemic cells in the bone marrow (Figure 18B). Interestingly, AML cells were not detectable in bone marrows of mice treated with PBMC followed by DNTs (Figure 18B). Given that CD8⁺ T cells are involved in both GvL and GvHD in PBMC treated group and that DNTs attenuate the severity of GvHD, the effect of DNT co-treatment on CD8 T cell-mediated GvL activity in PBMC+DNT-treated group was compared to that of PBMC-treated group. CD8⁺ T cells were isolated from PBMC- and PBMC+DNT-treated mice and used as effector cells against the leukemic cells initially used for the xenograft experiment. It was found that CD8⁺ T cells from both groups induce significant and comparable degree of cytotoxicity against the AML cells *ex vivo* (Figure 18C), suggesting that DNTs do not negatively affect the anti-leukemic activity of T_{conv} cells, while inducing anti-leukemia activity of their own to yield in a greater anti-leukemia activity in xenograft models. Together, these data support the notion that DNTs do not dampen GvL effect of T_{conv} cells, rather, they can increase the overall anti-leukemic response, which may lead to eradication of the disease.

[00166] Currently used methods of DNT isolation require obtaining whole blood from donors as CD4⁺ and CD8⁺ cells are depleted by cross-linking to erythrocytes. While this method has been successfully provided enough number to treat one to two patients, larger scale expansion is limited by the amount of blood

volume that can be safely drawn from a donor. Therefore, a method to scale-up DNT expansion by utilizing leukapheresis sample, instead of whole blood, will increase the amount of DNTs that can be expanded at once and maximize the off-the-shelf potential of DNT therapy. To this end, a starting DNT cell population was

5 isolated from PBMCs derived from leukapheresis using a selection column and DNTs with a mean purity of $89.5\% \pm 2.51\%$ (Figure 19A) were obtained. Further, DNTs obtained from PBMCs showed comparable expansion fold as those obtained from whole blood with an average expansion fold of 1899 ± 615.7 (Figure 19B). Lastly, DNTs expanded from PBMCs showed comparable *in vitro* cytotoxicity as

10 those isolated and expanded from whole blood (Figure 19C). These data demonstrate that DNTs can be isolated and expanded from PBMCs using the optimized method and show comparable characteristics as those isolated from whole blood.

[00167] Collectively, the results outlined in this patent demonstrate that DNTs

15 can be isolated and pooled from multi-donor leukapheresis samples to allow for large scale expansions that can be used to manufacture enough cellular products treat hundreds of patients from a single expansion culture rather than 2-3 patients using a maximal amount of whole blood that can be obtained from a single donor at one time.

20 [00168] All publications, patents and patent applications cited herein are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

REFERENCES

- 1 Park, J. H. *et al.* Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. *N. Engl. J. Med.* **378**, 449-459, doi:10.1056/NEJMoa1709919 (2018).
- 5 2 Tran, E. *et al.* T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. *N. Engl. J. Med.* **375**, 2255-2262, doi:10.1056/NEJMoa1609279 (2016).
- 3 Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. *Immunity* **39**, 49-60, doi:10.1016/j.immuni.2013.07.002 (2013).
- 10 4 Maus, M. V. *et al.* Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nat. Biotechnol.* **20**, 143-148, doi:10.1038/nbt0202-143 (2002).
- 5 FDA Approves Second CAR T-cell Therapy. *Cancer Discov* **8**, 5-6, doi:10.1158/2159-8290.CD-NB2017-155 (2018).
- 15 6 June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. *Sci Transl Med* **7**, 280ps287, doi:10.1126/scitranslmed.aaa3643 (2015).
- 7 Dickinson, A. M. *et al.* Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. *Front Immunol* **8**, 496, doi:10.3389/fimmu.2017.00496 (2017).
- 20 8 Chang, X., Zang, X. & Xia, C. Q. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. *Bone Marrow Transplant.* **51**, 324-332, doi:10.1038/bmt.2015.288 (2016).
- 25 9 Devillier, R. *et al.* Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. *Leuk. Lymphoma* **54**, 1228-1234, doi:10.3109/10428194.2012.741230 (2013).
- 10 Zeiser, R. & Blazar, B. R. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. *N. Engl. J. Med.* **377**, 2167-2179, doi:10.1056/NEJMra1609337 (2017).
- 30 11 Zeiser, R. & Blazar, B. R. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. *N. Engl. J. Med.* **377**, 2565-2579, doi:10.1056/NEJMra1703472 (2017).
- 35 12 Ruella, M. & Kenderian, S. S. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. *BioDrugs* **31**, 473-481, doi:10.1007/s40259-017-0247-0 (2017).
- 13 Chen, B., Lee, J. B., Kang, H., Minden, M. D. & Zhang, L. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. *J. Exp. Clin. Cancer Res.* **37**, 88, doi:10.1186/s13046-018-0756-9 (2018).
- 40 14 Lee, J. *et al.* Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms. *Clinical Cancer Research (provisionally accepted)* (2017).

- 15 Merims, S. *et al.* Anti-leukemia effect of ex vivo expanded DNT cells from
AML patients: a potential novel autologous T-cell adoptive immunotherapy.
Leukemia **25**, 1415-1422, doi:10.1038/leu.2011.99 (2011).
- 16 Lee, J. B. *et al.* Developing Allogeneic Double-Negative T Cells as a Novel
5 Off-the-Shelf Adoptive Cellular Therapy for Cancer. *Clin. Cancer Res.* **25**,
2241-2253, doi:10.1158/1078-0432.CCR-18-2291 (2019).
- 17 Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G. & Sewell, A. K. CRISPR-
mediated TCR replacement generates superior anticancer transgenic T
cells. *Blood* **131**, 311-322, doi:10.1182/blood-2017-05-787598 (2018).
- 10 18 Poirot, L. *et al.* Multiplex Genome-Edited T-cell Manufacturing Platform for
"Off-the-Shelf" Adoptive T-cell Immunotherapies. *Cancer Res.* **75**, 3853-
3864, doi:10.1158/0008-5472.CAN-14-3321 (2015).
- 19 Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building
the ultimate antitumour T cell. *Nat. Rev. Cancer* **12**, 671-684,
15 doi:10.1038/nrc3322 (2012).
- 20 Torikai, H. & Cooper, L. J. Translational Implications for Off-the-shelf
Immune Cells Expressing Chimeric Antigen Receptors. *Mol. Ther.* **24**, 1178-
1186, doi:10.1038/mt.2016.106 (2016).
- 21 Torikai, H. *et al.* Toward eliminating HLA class I expression to generate
20 universal cells from allogeneic donors. *Blood* **122**, 1341-1349,
doi:10.1182/blood-2013-03-478255 (2013).
- 22 Rosenbaum, L. Tragedy, Perseverance, and Chance - The Story of CAR-T
Therapy. *N. Engl. J. Med.* **377**, 1313-1315, doi:10.1056/NEJMp1711886
(2017).
- 25 23 Gedye, C. A. *et al.* Cell surface profiling using high-throughput flow
cytometry: a platform for biomarker discovery and analysis of cellular
heterogeneity. *PLoS ONE* **9**, e105602, doi:10.1371/journal.pone.0105602
(2014).
- 24 Chimenti, I. *et al.* Serum and supplement optimization for EU GMP-
30 compliance in cardiospheres cell culture. *J. Cell. Mol. Med.* **18**, 624-634,
doi:10.1111/jcmm.12210 (2014).
- 25 O'Boyle, G. *et al.* Chemokine receptor CXCR3 agonist prevents human T-
cell migration in a humanized model of arthritic inflammation. *Proc. Natl.*
Acad. Sci. U. S. A. **109**, 4598-4603, doi:10.1073/pnas.1118104109 (2012).
- 35 26 Hirota, K. *et al.* Preferential recruitment of CCR6-expressing Th17 cells to
inflamed joints via CCL20 in rheumatoid arthritis and its animal model. *J.*
Exp. Med. **204**, 2803-2812, doi:10.1084/jem.20071397 (2007).
- 27 Oswald, C. *et al.* Intracellular allosteric antagonism of the CCR9 receptor.
Nature **540**, 462-465, doi:10.1038/nature20606 (2016).
- 40 28 Woods, E. J., Thirumala, S., Badhe-Buchanan, S. S., Clarke, D. & Mathew,
A. J. Off the shelf cellular therapeutics: Factors to consider during
cryopreservation and storage of human cells for clinical use. *Cytotherapy* **18**,
697-711, doi:10.1016/j.jcyt.2016.03.295 (2016).
- 45 29 Dudley, M. E. & Rosenberg, S. A. Adoptive-cell-transfer therapy for the
treatment of patients with cancer. *Nat. Rev. Cancer* **3**, 666-675,
doi:10.1038/nrc1167 (2003).

- 30 Boni, A. *et al.* Adoptive transfer of allogeneic tumor-specific T cells mediates
effective regression of large tumors across major histocompatibility barriers.
Blood **112**, 4746-4754, doi:10.1182/blood-2008-07-169797 (2008).
- 31 Chambers, J. D. & Neumann, P. J. Listening to Provenge--what a costly
5 cancer treatment says about future Medicare policy. *N. Engl. J. Med.* **364**,
1687-1689, doi:10.1056/NEJMp1103057 (2011).
- 32 Brenner, M. K. Will T-cell therapy for cancer ever be a standard of care?
Cancer Gene Ther. **19**, 818-821, doi:10.1038/cgt.2012.74 (2012).
- 33 Sheridan, C. Allogene and Celularity move CAR-T therapy off the shelf. *Nat.*
10 *Biotechnol.* **36**, 375-377, doi:10.1038/nbt0518-375 (2018).
- 34 Yao, J. *et al.* Human double negative T cells target lung cancer via ligand-
dependent mechanisms that can be enhanced by IL-15. *Journal for*
ImmunoTherapy of Cancer volume 7, Article number: 17 (2019),
doi:https://doi.org/10.1186/s40425-019-0507-2.
- 15 35 Jacoby, E. *et al.* Murine allogeneic CD19 CAR T cells harbor potent
antileukemic activity but have the potential to mediate lethal GVHD. *Blood*
127, 1361-1370, doi:10.1182/blood-2015-08-664250 (2016).
- 36 Provasi, E. *et al.* Editing T cell specificity towards leukemia by zinc finger
nucleases and lentiviral gene transfer. *Nat. Med.* **18**, 807-815,
20 doi:10.1038/nm.2700 (2012).
- 37 Young, K. J., Kay, L. S., Phillips, M. J. & Zhang, L. Antitumor activity
mediated by double-negative T cells. *Cancer Res.* **63**, 8014-8021 (2003).
- 38 Young, K. J., DuTemple, B., Zhang, Z. X., Levy, G. & Zhang, L. CD4-CD8-
regulatory T cells implicated in preventing graft-versus-host and promoting
25 graft-versus-leukemia responses. *Transplant. Proc.* **33**, 1762-1763,
doi:10.1016/s0041-1345(00)02670-1 (2001).
- 39 Bian, Z. *et al.* Association of Epstein-Barr virus reactivation with the recovery
of CD4/CD8 double-negative T lymphocytes after haploidentical
hematopoietic stem cell transplantation. *Bone Marrow Transplant.* **52**, 264-
30 269, doi:10.1038/bmt.2016.238 (2017).
- 40 Suck, G. *et al.* NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer
cell-based cancer immunotherapy. *Cancer Immunol. Immunother.* **65**, 485-
492, doi:10.1007/s00262-015-1761-x (2016).
- 41 Tonn, T. *et al.* Treatment of patients with advanced cancer with the natural
35 killer cell line NK-92. *Cytotherapy* **15**, 1563-1570,
doi:10.1016/j.jcyt.2013.06.017 (2013).
- 42 Romee, R. *et al.* Cytokine-induced memory-like natural killer cells exhibit
enhanced responses against myeloid leukemia. *Sci Transl Med* **8**, 357ra123,
doi:10.1126/scitranslmed.aaf2341 (2016).
- 40

CLAIMS:

1. A method of producing a population of double negative T cells (DNTs) for therapeutic applications, the method comprising:
 - a. providing a sample population of DNTs, wherein the sample population of DNTs comprises DNTs from one or more donors;
 - b. culturing the sample population of DNTs in a culture media to produce an expanded population of DNTs,
 - c. re-suspending the expanded population of DNTs in a storage medium; and optionally
 - d. adding DMSO to the storage medium to a final concentration of between about 3% and about 15% DMSO, optionally between about 5% and 10% DMSO.
2. The method of claim 1, comprising adding DMSO to the storage medium to a final concentration of between about 3% and about 15% DMSO, optionally between about 5% and 10% DMSO.
3. The method of claim 1 or 2, wherein the sample population of DNTs comprises DNTs from two or more donors, and DNTs in the expanded population of DNTs are not alloreactive against one another.
4. The method of any one of claims 1 to 3, wherein the culture media is animal serum-free media.
5. The method of claim 4, wherein the culture media comprises AIM-V, GT-T551, Stemline T cell Expansion Medium, Immunocult-XF T cell Expansion Medium, Human StemXVivo, Serum-Free Human T cell Base Media, CTS T-cell Expansion SFM, Prime-XV T cell expansion XSFM, or an equivalent human T cell culture media without animal-derived components.

6. The method of any one of claims 1 to 5, wherein the culture media further comprises human blood-derived components, plasma, serum, or HSA, optionally human plasma.
7. The method of claim 6, wherein the human blood-derived component is autologous to the sample population of DNTs.
8. The method of claim 6, wherein the human blood-derived component is allogenic to the sample population of DNTs.
9. The method of claim 6, wherein the human blood-derived component comprises a human blood-derived component from one or more donors.
10. The method of any one of claims 6 to 9, wherein the human blood-derived component in the culture media is at a concentration of 1-20%.
11. The method of any one of claims 1 to 10, wherein the culture media comprises recombinant IL-2, IL-15, IL-7, IFN γ , an anti-4-1BB, anti-CD28, anti-OX40, anti-ICOS, anti-CD40, recombinant CD83, MIP-1a, IL-6, IL-8, IL-21, Jq1 inhibitor and/or anti-CD3.
12. The method of claim 11, wherein the culture media comprises between about 50 and 800 IU/ml IL-2 and/or between about 0.05 and 1 μ g/ml anti-CD3.
13. The method of any one of claims 1 to 12, wherein the sample population of DNTs comprises DNTs from peripheral blood and the expanded population of DNTs yields at least 0.2, 0.5, 0.8 or 1.0 x 10⁸ DNTs per millilitre of peripheral blood.
14. The method of any one of claims 1 to 13, wherein the expanded population of DNTs comprises at least 80% DNTs, optionally at least 90% DNTs.

15. The method of any one of claim 1 to 14 comprising splitting the cells to maintain a cell population above 0.1 million per ml of the culture media and below 4 million per ml of the culture media and/or wherein the method comprises culturing the DNTs for at least 5 days, at least 8 days, at least 10 days, at least 12 days, at least 14 days, at least 17 days, at least 20 days, or at least 25 days, optionally between 10 days and 20 days.
16. The method of any one of claims 1 to 15, wherein the sample population of DNTs comprises DNTs from peripheral blood, leukopheresis, Leukopak, bone marrow and/or cord blood samples.
17. The method of any one of claims 1 to 16, wherein the population of DNTs is genetically modified.
18. A method for cryopreserving double negative T cells (DNTs), the method comprising:
 - a. re-suspending a population of DNTs in a storage medium;
 - b. adding DMSO to the storage medium to a final concentration of between about 5% and about 10% DMSO; and
 - c. cryopreserving the population of DNTs in the storage medium at a temperature less than -70°C.
19. The method of claim 18, wherein the population of DNTs has been expanded *ex vivo*, optionally wherein the population has been expanded according to the method of any one of claims 1 to 17, prior to re-suspending the population of DNTs in the storage medium.
20. The method of claim 19, wherein the cells are expanded *ex vivo* for between 5 and 25 days, optionally between about 8 and 20 days, or about 10 days prior to cryopreserving the cells.

21. The method of any one of claims 18 to 20, wherein the DNTs are at a final concentration in the storage medium of between about 2.5×10^7 and about 2.5×10^8 cells/ml optionally between about $5-10 \times 10^7$ cells/ml.
22. The method of any one of claims 18 to 21, wherein the population of DNTs is resuspended in storage medium cooled to less than 10°C but not frozen, optionally wherein the storage medium is cooled to about 8°C , 6°C , 4°C , or 2°C .
23. The method of any one of claims 18 to 22, wherein the DMSO prior to being added to the storage medium is at a concentration of about 10% to about 20%, optionally at a concentration of about 10%, about 15% or about 20% of storage medium.
24. The method of any one of claims 18 to 23, wherein the final concentration of DMSO is from about 5% to about 8.5%, optionally about 7.5%.
25. The method of any one of claims 18 to 24, wherein the storage medium comprises animal serum, optionally fetal bovine serum.
26. The method of any one of claims 18 to 24, wherein the storage medium is animal serum free, preferably Cryostor™.
27. The method of any one of claims 18 to 26, further comprising storing the cryopreserved cells at a temperature less than -130°C , optionally in liquid nitrogen.
28. The method of claim 27, comprising storing the population of DNTs at the temperature between -70°C to -90°C for at least 8 hours, at least 10 hours, at least 12 hours or at least 16 hours prior to storing the cryopreserved cells at the temperature less than -130°C .

29. A population of DNTs produced according to any one of claims 1-17 or cryopreserved according to any one of claims 18 to 28, optionally wherein the DNTs can be cryopreserved without losing viability and/or function for at least 10 days, at least 300 days, at least 400 days, or at least 600 days.
30. A population of DNTs cryopreserved according to the method of any one of claims 18 to 29, wherein the population of DNTs comprises DNTs from two or more donors and is for use or administration in one or more subjects for the treatment of cancer.
31. A population of DNTs produced according to any one of claims 1 to 17, or cryopreserved according to any one of claims 18 to 28, wherein the DNTs express one or more surface markers, cytokines and/or chemokines.
32. The population of DNTs of claim 31, wherein the population of DNTs express CD3 and do not express CD4 or CD8 prior to expansion, and/or express CD3 and do not express CD4 or CD8 at least 5 days, 10 days, 14 days, 17 days, or 20 days post expansion.
33. The population of DNTs of claim 31 or 32, wherein the DNTs are CD11a+, CD18+, CD10-, and/or TCR V α 24-J α 18-.
34. The population of DNTs of claim 31 or 32, wherein the DNTs are CD49d+, CD45+, CD58+ CD147+ CD98+ CD43+ CD66b- CD35- CD36- and/or CD103-
35. The population of DNTs of any one of claims 31 to 34, wherein the surface markers comprise one or more cytotoxic molecules such as perforin, granzymes TRAIL, NKG2D, DNAM-1, NKp30 and/or KIR2DS4, immune co-stimulatory molecules such as CD28, CD27, CD30, GITR, CD40L and/or HVEM, immune co-inhibitory molecules such as TIM-3, LAIR1, NKG2A, CD94,

- LAG-3, CD160 and/or BTLA, adhesion molecules such as LFA-1, CD44, CD49d and/or CD62L, and/or chemokine receptors such as CXCR3, CCR3, CCR6 and/or CCR9, cytokine receptors such as CD122 and/or CD127.
36. A method to enhance activity of DNTs, the method comprising inhibiting immune co-inhibitory molecules using anti-TIM3, anti-NKG2A, anti-LAIR1, anti-CD94, anti-LAG3, anti-CD160 and/or anti-BTLA antagonistic agents, and/or through enhancing immune co-stimulatory molecules using anti-CD28, anti-CD27, anti-GITR, anti-CD40L, anti-HVEM and/or anti-CD30 agonistic agents.
37. A method to modulate tissue trafficking and homing of DNTs comprising inducing or delivering adhesion ligands/receptors to CD44, CD49d and/or CD62L and/or chemokines to CXCR3, CCR3, CCR6 and/or CCR9 at desired target tissues and locations.
38. A population of DNTs produced according to any one of claims 1 to 17, or cryopreserved according to any one of claims 18 to 28, wherein the DNTs have no or low expression of immune co-inhibitory molecules PD-1, and/or CTLA-4, are resistant to PD-1 and/or CTLA-4 pathway mediated T cell suppression and exhaustion, and/or cancer immune suppression or escape mechanisms.
39. A population of DNTs according to any one of claims 29-35 or 38, wherein the population of DNTs is not cytotoxic against allogeneic normal cells *in vitro*.
40. A population of DNTs according to any one of claims 29-35, 38 or 39, wherein the population of DNTs is not cytotoxic against allogeneic and xenogeneic normal cells *in vivo*.
41. A population of DNTs according to any one of claims 29-35 or 38-40, wherein the population of DNTs is resistant to allogeneic immune cell-mediated rejection in the subject *in vivo*.

42. A population of DNTs according to any one of claims 29-35 or 38-41, wherein the population of DNTs is not genetically modified to reduce or prevent expression of TCR and/or MHC-I/II.
43. A population of DNTs according to any one of claims 29-35 or 38-42, wherein the population of DNTs is genetically modified to enhance their anti-tumor activities and to reduce the risk to recipients.
44. A population of DNTs according to any one of claims 29-35 or 38-43, wherein allogenic DNTs from the two or more donors are combined prior to being expanded *ex vivo*.
45. A population of DNTs according to any one of claims 29-35 or 38-43, wherein the allogenic DNTs from the two or more donors are expanded *ex vivo* separately prior to being combined to form the population of DNTs.
46. A population of DNTs according to any one of claims 29-35 or 38-45, wherein the population of DNTs persists in the subject for at least 24 hours, or at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days, at least 10 days, at least 2 weeks, at least 3 weeks, or at least 4 weeks.
47. Use of the population of DNTs according to any one of claims 29-35 or 38-46 for the treatment of cancer in a subject in need thereof.
48. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the population of DNTs according to any one of claims 29-35 or 38-46.
49. Use of an effective amount of a population of DNTs for treating cancer in a subject in need thereof, wherein the population of DNTs comprises allogenic DNTs from one or more donors.

50. The use of claim 49, wherein the population of DNTs comprises allogenic DNTs from two or more donors.
51. The method or use of any one of claims 48 to 50, wherein the subject is not administered immunosuppression therapy prior to or during the use or administration of the population of DNTs.
52. The method or use of any one of claims 48 to 51, wherein the population of DNTs is from a single expansion of DNTs from one or more donors, and is for a single or multiple use or administration to a single cancer patient.
53. The method or use of any one of claims 48 to 50, wherein the population of DNTs is from a single expansion of DNTs from one or more donors and is for a single or multiple use or administration to multiple subjects for the treatment of cancer.
54. The method or use of any one of claims 48 to 53, wherein the allogenic DNTs have been expanded *ex vivo*, optionally wherein the allogenic DNTs have been expanded according to the method of any one of claims 1 to 17 and/or cryopreserved according to any one of claims 18 to 30.
55. The method or use of any one of claims 48 to 54, further comprising the use or administration of a population of allogenic Hematopoietic Stem Cells (allo-HSCs) to the subject.
56. The method or use of claim 55, wherein the allo-HSCs are from peripheral blood, leukapheresis, bone marrow or cord blood, optionally wherein the allo-HSCs are mobilized using G-CSF.
57. The method or use of claim 55 or 56, wherein the DNTs are for use or administered to the subject at the same time as the allo-HSCs or at different times.

58. The method or use of any one of claims 55 to 57, wherein DNTs and HSCs are from the same or different donors.
59. The method or use of any one of claims 48 to 58, further comprising the use or administration of a population of peripheral blood mononuclear cells (PBMCs) to the subject.
60. The method or use of claim 58, wherein the PBMCs are lymphocytes, optionally conventional CD4+ CD8+ T cells.
61. The method or use of claim 59 or 60, wherein the DNTs are administered to the subject at the same time as the PBMCs or at different times.
62. The method or use of any one of claims 48 to 61, further comprising the use or administration of an antibody to CD3.
63. The method or use of any one of claims 48 to 62, for the treatment of non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma or acute or chronic myeloid or lymphocytic leukemia in the subject.
64. A method of expanding a population of double negative T cells (DNTs) *ex vivo*, the method comprising:
- a) providing a sample population of DNTs, wherein the sample population of DNTs comprises DNTs from two or more donors;
 - b) culturing the sample population of DNTs in a culture media to produce an expanded population of DNTs.
65. The method of claim 64, wherein the DNTs from a first donor are not alloreactive against DNTs from a second donor in the expanded population of DNTs.

66. The method of claim 64 or 65, wherein the culture media is animal serum-free media, optionally AIM-V.

67. The method of any one of claims 64 to 66, wherein the culture media further comprises plasma, optionally human plasma.

68. The method of claim 67, wherein the plasma is allogenic to the sample population of DNTs, optionally wherein the plasma comprises plasma from two or more donors.

69. The method of claim 67 or 68, wherein the plasma in the culture media is at a concentration of 2-15%.

70. The method of any one of claims 64 to 69, wherein the sample population of DNTs comprises DNTs from peripheral blood, optionally wherein the expanded population of DNTs yields at least 0.5, 0.8 or 1.0×10^8 DNTs per milliliter of peripheral blood.

71. The method of any one of claims 64 to 70, wherein the expanded population of DNTs comprises at least 80% DNTs, optionally at least 85% or 90% DNTs.

72. The method of any one of claim 64 to 71, comprising splitting the cells to maintain a cell population above 0.1 million per ml of the culture media and below 4 million per ml of the culture media.

73. A method for cryopreserving double negative T cells (DNTs), the method comprising:


- a) re-suspending a population of DNTs in a storage medium;
- b) adding DMSO to the storage medium to a final concentration of between about 5% and about 15% DMSO; and
- c) cryopreserving the population of DNTs in the storage medium at a temperature less than -70°C .

74. The method of claim 73, further comprising expanding the population of DNTs *ex vivo* according to the method of any one of claims 64 to 72 prior to step a).

75. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a population of DNTs expanded according to the method of any one of claims 64 to 72 and/or cryopreserved according to the method of claim 73 or 74.

76. Use of a population of DNTs expanded according to the method of any one of claims 64 to 72 and/or cryopreserved according to the method of claim 73 or 74 for the treatment of cancer in a subject in need thereof.

A



B





FIG. 1

C



D




FIG. 1 (CONT.)





FIG. 1 (CONT.)

G



H





FIG. 1 (CONT.)

I



J




FIG. 1 (CONT.)

6/29

K





FIG. 1 (CONT.)

A



B





FIG. 2

8/29

C



D

EBV-LCL





FIG. 2 (CONT.)

9/29

E



F





FIG. 2 (CONT.)

10/29

G



H





FIG. 2 (CONT.)

11/29

A



B





FIG. 3

12/29

C



D





FIG. 3 (CONT.)

A



B





FIG. 4

14/29

C



D





FIG. 4 (CONT.)

E



F




FIG. 4 (CONT.)

G




FIG. 4 (CONT.)




FIG. 5




FIG. 6





FIG. 7

A



B





FIG. 8

20/29

A



B




FIG. 9

21/29





FIG. 10




FIG. 11

23/29




FIG. 12






FIG. 13

24/29

A



B



C




FIG. 14

25/29





FIG. 15

D



E




FIG. 15 (CONT.)

27/29




FIG. 16






FIG. 17

28/29

A.



B.



C.




FIG. 18




FIG. 19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2019/051866

A. CLASSIFICATION OF SUBJECT MATTER
IPC: *C12N 5/0783* (2010.01), *A01N 1/02* (2006.01), *A61K 35/17* (2015.01), *A61P 35/00* (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC: ALL

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
None

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
Questel-Orbit and PubMed (keywords: "double negative", T-cell, storage, cancer, therapy, tumour, CD44, homing, chemokine, target*, regression, engineer*, antitumor, Zhang, L, Lee, J.)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	WO2007056854A1 (ZHANG, L. et al.) 24 May 2007 (24-05-2007) whole document	1-12, 14-16, 18-20, 23-25, 27-34, 39-42, 44-54, 59-69 and <u>71-76</u> 13, 17, 21, 22, 35, 36, 43, 55-58 and 70
Y	CHEN, B. et al. "Targeting Chemotherapy-Resistant Leukemia by Combining DNT Cellular Therapy with Conventional Chemotherapy". J. Exp. Clin. Cancer Res. 2018. Vol. 37, pp 1-11 ISSN: 1756-9966 (Electronic) whole document	35 and 55-58
Y	LEE, J. et al. "Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms". Clin. Cancer Res. 2018. Vol. 24, pp 370-82 ISSN: 1078-0432 (Electronic) whole document	13, 21, 22 and 70

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"D" document cited by the applicant in the international application	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"E" earlier application or patent but published on or after the international filing date	"&" document member of the same patent family
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
07 February 2020 (07-02-2020)

Date of mailing of the international search report
28 February 2020 (28-02-2020)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 819-953-2476

Authorized officer

Philip Marshall (819) 639-5251

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2019/051866

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ANKRI, C. et al. "Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity". J. Immunol. 2013. Vol. 191, pp 4121-29 ISSN: 1550-6606 whole document	17, 36 and 43
A	SINGH, V. et al. "Cooperativity of CD44 and CD49d in Leukemia Cell Homing, Migration, and Survival Offers a Means for Therapeutic Attack". J. Immunol. 2013. Vol. 191, pp 5304-16 ISSN: 1550-6606	

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The claims are directed to a plurality of inventive concepts as follows:

Group A - Claims 1-17, 29-35 (partially), 38-63 (partially), 64-72, 75 (partially) and 76 (partially) are directed to a method of producing a population of double negative T cells (DNTs) from one or more donors, a population of DNTs produced by said method, a method of treating cancer by administering DNTs, use of DNTs for treating cancer, a method of expanding a population of DNTs from two or more donors and use of said expanded DNTs;

Group B – Claims 18-28, 29-35 (partially), 38-63 (partially), 73, 74, 75 (partially) and 76 (partially) are directed to a method of cryopreserving DNTs, a population of DNTs produced by said method, a method of treating cancer by administering DNTs, use of DNTs for treating cancer, a method for cryopreserving DNTs at less than -70°C and use of said cryopreserved DNTs;

(continued on page 6)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

(continued from box III on page 2)

Group C - Claim 36 is directed to a method to enhance activity of DNTs by inhibiting co-inhibitory molecules; and

Group D - Claim 37 is directed to a method to modulate tissue trafficking and homing of DNTs.

The claims must be limited to one inventive concept as set out in PCT Rule 13. The only common feature between claims of groups A to D is DNTs but said DNTs were well known in the art at the time of filing as exemplified by D1. Therefore, there is no single inventive general concept linking claims of groups A to D and each claim group is considered a separate invention.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2019/051866

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2007056854A1	24 May 2007 (24-05-2007)	CA2629532A1	24 May 2007 (24-05-2007)
		CA2629532C	09 August 2016 (09-08-2016)
		CN101313061A	26 November 2008 (26-11-2008)
		CN101313061B	15 May 2013 (15-05-2013)
		EP1948788A1	30 July 2008 (30-07-2008)
		EP1948788A4	01 July 2009 (01-07-2009)
		US2009098095A1	16 April 2009 (16-04-2009)
		US9018004B2	28 April 2015 (28-04-2015)
		US2016045550A1	18 February 2016 (18-02-2016)
		US9925220B2	27 March 2018 (27-03-2018)